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SUMMARY 
 
Duchenne muscular dystrophy (DMD) caused by mutations in the dystrophin gene is a 
severe chronic muscle-wasting disease leading to early loss of ambulation in patients and to 
death by the third decade. Other muscular dystrophies exist including amongst others DMD’s 
milder allelic form Becker muscular dystrophy and the heterogeneous group of limb-girdle 
muscular dystrophies that differ in age of onset, severity, and affected proteins.  
In diagnosing muscular dystrophies, the assessment of multiple proteins in a muscle biopsy 
by immunohistochemical methods is considered the gold standard, as the identification of the 
underlying mutation is not always feasible or sufficient due to difficult genotype-phenotype 
prediction. The reproducibility and sensitivity of reverse protein arrays and their excellent 
correlation with immunohistochemistry and immunoblotting combined with minimal sample 
and antibody consumption make them an ideal approach for the assessment of muscular 
expression of multiple proteins in small biopsies. We have evaluated a set of antibodies 
currently used in standard diagnostic processes for muscular dystrophies on human muscle 
tissue and cultured primary human myotubes. We have found high correlations with Western 
blot data and reproducible significant differences in dystrophin, sarcoglycan, and 
dystroglycan expression between control and patient samples. Reverse protein arrays can 
quantitatively measure muscle proteins in as little as 10mg muscle tissue. This technology 
could be of interest not only in diagnostic processes, but especially for protein quantification 
of multiple, follow-up biopsies during clinical trials in upcoming therapy approaches when 
protein expression in muscle is considered an important outcome measure or biomarker.  
Despite the precise and extensive knowledge about the dystrophin gene and its protein, 
precise molecular and cellular events that eventually lead to muscle fiber degeneration in 
DMD are poorly understood. Downstream pathogenic events in metabolic pathways and 
cellular signaling that are key factors causing the ultimate degeneration of muscle fibers in 
DMD and reflecting disease state can be elucidated using mass spectrometry-based 
proteomics experiments. Proteomic profiling of DMD muscle tissue and comparing the 
resulting pattern to other muscular dystrophies has revealed a set of proteins that are 
differentially expressed in DMD skeletal muscle, most prominently a drastic increase in the 
muscle-specific member of the small heat shock protein family HSPβ2. We are currently 
implementing a set of experiments to validate HSPβ2 as disease marker for Duchenne 
muscular dystrophy in cultured primary myotubes from DMD patients and, if applicable, in 
serum from DMD patients. HSPβ2 is a promising candidate that could be applied as 
signature molecule as part of a protein panel that can be used to assess disease state in 
DMD or therapeutic effects of novel drugs or treatments. 
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1. INTRODUCTION  
 
1.1. General Introduction 
1.1.1. Human muscle – forms and development  
Human muscle consists of three tissue forms: Smooth muscle, skeletal muscle and cardiac 
muscle. Skeletal muscle accounts for about 40% of total human body mass. Cardiac muscle 
and skeletal muscle are alternatively named striated muscle due to the characteristic striated 
appearance of I-bands and A-bands in polarizing microscopy. In contrast to other muscles, 
contraction of skeletal muscle is voluntary because it is controlled by the nervous system. 
In the embryo, proliferating precursor cells from the dermatomyatome of the developing 
somite coalesce into cells that will differentiate into skeletal muscles. Upon the activation of 
muscle-specific genes, the cells become myoblasts (mononuclear undifferentiated muscle 
cells). Myogenic determination factors activate regulatory regions of genes that code for the 
skeletal muscle-specific structural and functional proteins. Calcium ions and adhesion 
molecules such as N-cadherin and the neural cell adhesion molecule (NCAM) induce the 
fusion of postmitotic myoblasts to multinucleated myotubes [1]. As myotubes grow further, 
the initially centrally located nuclei migrate to the periphery of the myotubes and the 
myofibrils are differentiated into muscle fibers. Induction of myogenin mRNA is the earliest 
known event accompagnying myogenic differentiation. 
1.1.2. Skeletal muscle structure 
Skeletal muscle is composed of parallel multinucleated muscle fibers and connective tissue. 
Muscle fibers consist of cylindrical myofibrils surrounded by a membrane of the sarcoplasmic 
reticulum (SR). Based on morphological, electrophysiological, biochemical and functional 
characteristics, muscle fibers can be classified as slow-twitch (type I) or fast-twitch (type II) 
muscle fibers. Fast-twitch muscle fibers can be further divided into subtypes IIa, IIb, and IIc 
according to their myosin heavy chain (MHC) type, number of mitochondria, and metabolism 
type [1]. Examples for slow-twitch muscle are cardiac muscles or the soleus, examples for 
fast twitch muscle include the quadriceps femoris or gastrocnemius. Muscles vary 
considerably in their contents of fast- and slow-twitch muscle fibers. In superficial muscle 
regions fast-twitch fibers are more abundant whereas in deeper muscle layers slow-twitch 
muscle fibers are predominant [2].  
The parallel myofibrils in the single muscle fibers lead to a longitudinal striation visible in 
polarizing microscopy. Physical activity can enhance the number and diameter of myofibrils, 
whereas the number and mass of myofibrils decrease during inactivity (hypothrophy). 
Myofibrils are in turn composed of myofilaments (thick myofilaments: myosin and myosin-
binding proteins C, H, and X (A-bands); thin myofilaments: actin, troponin and tropomyosin 
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(I-bands)) that account for their transverse striation in polarizing or phase contrast 
microscopy [1, 3]. Troponin and tropomyosin form a complex that plays a role in the 
regulation of muscle contraction upon Ca2+ activation [3]. The elementary contractile unit of 
skeletal muscle is the sarcomere exerting crucial functions as rapid and efficient shortening, 
switching on/off in milliseconds and precise self-assembly as well as structural regularity [3]. 
Sarcomeres extend from Z-line to Z-line in the I-bands (see Figure 1). In the middle section 
of the A-bands ranging over the thick filaments lies the slightly lighter appearing H-zone 
where myosin filaments have no globular structures. The H-zone contains the M-Line 
appearing as thin dark band containing creatine kinase (CK), myomesin, protein M, skelemin 
as well as cross-bridges of myosin filaments. Here, myosin filaments are precisely arranged 
in their parallel structure. One thick filament is composed of about 300 molecules of myosin II 
and associated non-myosin proteins [3]. F-actin being the main component of the I-bands is 
composed of 14 polymerized G-actin monomers each containing one myosin binding site 
arranged in a double-helical structure. One molecule of tropomyosin is attached to each 
seven actin monomers. Z-lines of α-actinin, myotilin, theletonin and other proteins divide the 
I-bands into two zones and mark the beginning and end of each sarcomere. Nebulin 
(connecting Z-lines and actin) and titin (connecting M-lines and Z-lines) parallel the thick and 
thin myofilaments and mediate longitudinal stability of the sarcomeres as well as length 
determination of the filaments [3].  
 
 
Figure 1: Schematic representation of the sarcomere extending from Z-band to Z-band in the myofibril 
 9
Space between myofilaments contains mitochondria, SR and glycogen. The cytoskeleton of 
muscle fibers consists of the endosarcomeric and the exosarcomeric part and is built from a 
complex three-dimensional scaffold of microtubules, cytoskeletal actin filaments and 
intermediate filaments. This scaffold maintains structural and mechanical integrity of the 
muscle fiber during contraction and exhibits high flexibility and stability. Intermediate 
filaments of the exosarcomeric cytoskeleton are divided into five classes: I contains the 
acidic cytokeratins, II the basic cytokeratins, III desmin, vimentin, synemin and paranemin, IV 
syncoilin, desmuslin, and nestin, and V lamins A/C and B. Desmin, the main intermediate 
filament protein in adult muscle, forms the cytoskeleton particularly at the Z-disk, but also 
extending longitudinally along the myofibrils and towards the plasmalemma. The >500kDa 
protein plectin is an intermediate filament linker connecting desmin (and probably also other 
intermediate filaments such as syncoilin and desmuslin) to the Z-disks and to the peripheral 
cytoskeleton. Intermediate filaments protect the muscle cells against mechanical stress. 
Other intermediate filament proteins are probably present in adult muscle, as the knockout of 
desmin does not have a great impact on myofibril alignment, and plectin localization at the Z-
disks persists. Upon denervation, however, the levels of intermediate filament proteins in 
muscle fibers decrease. 
Costameres are agglomerations of proteins localized subsarcolemmal at the Z-lines. They 
entirely surround the muscle fibers and thereby maintain the sarcolemma in the direction of 
the sarcomeres, protect sarcomeres from mechanical damage and partially transfer lateral 
force that is generated during contraction to the extracellular matrix (ECM) and other muscle 
fibers. Costameres contain cytokeratins, α-actin and β-spectrin (among others). Muscle fibers 
contain two independent membrane systems: the sarcoplasmatic reticulum and the 
transversal (T-) tubuli (invaginations of the sarcolemma). Nuclei in healthy human muscle are 
located in a subsarcolemmal position at the periphery of the muscle fibers.  
 
Cytoskeleton in muscle plays an important role (structural and supportive) in force 
transmission and connection between myofibrils and sarcolemma (the basal lamina with the 
lipid bilayer undercoated by subsarcolemmal actin network). The lipid bilayer of the 
plasmalemma is mechanically not very stable and is protected from mechanical stress 
externally by the basal lamina and internally by the actin network. These two layers are 
strongly attached to each other across the plasmalemma at the costameres and between 
costameres by the dystrophin-glycoprotein complex (DGC) or integrins [4]. Integrins are 
heterodimeric cell surface receptors binding cytoskeletal elements and playing an important 
role in transmembrane signaling. In skeletal muscle, integrins are found in the lateral surface 
of muscle cells, especially at costameres stabilizing junctions and playing a role in muscle 
differentiation [4]. α7-integrin expression for example is restricted to a few cell types including 
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skeletal muscle. The cytoskeleton in muscle cells consists of four components: 
subsarcolemmal network, transverse connecting system, protein complex connecting 
myofibrils to sarcolemmal folds at myotendinous junction (MTJ), and microtubules. The 
structure-protecting transverse connecting system links myofibrils to the intermediate 
filament network and to the actin-based cytoskeleton of the muscle cell. Three multimolecular 
complexes are known: the focal adhesion type (integrins), the dystrophin/utrophin-based 
complex and spectrin-based membrane skeleton systems. The neuromuscular junction 
(NMJ) maintains high density of acetylcholine receptors and acetylcholinesterase as well as 
close proximitiy with motor nerve terminals. Dystrophin, utrophin and spectrin are highly 
expressed at the NMJ and probably stabilize it. The MTJ is responsible for longitudinal force 
transmission from the ends of the myofibrils to the tendons. As this site requires extreme 
mechanical stability, injury in DMD often occurs here.  
1.1.3. Function of human skeletal muscle  
Many modes of cellular movement require the interaction of actin filaments and myosin as 
motor protein. The highly coordinated contraction of skeletal muscle is also mediated by this 
interaction, through the actin-myosin sliding mechanism. It was thought early that during 
muscle contraction, filaments shorten and somehow fold internally in order for the muscle to 
contract. The observation that during contraction the A band remains constant in length led 
to the sliding-filament model, which is generally accepted today namely that filaments remain 
constant in length while the muscle contracts [3]. Muscle contraction transmits metabolic 
energy that is stored in the muscle cells into mechanical work [5].  
Actin and myosin are responsible for this transduction of chemical energy to mechanical 
force during muscle contraction. By hydrolyzing adenosine triphosphate (ATP), the proteins 
are linked with the energy source for contraction [3]. When no ATP is present myosin (thick 
filament) is stably bound to actin via its globular subunit, the head domain (state of rigor 
mortis). In relaxed muscle state, tropomyosin and troponin prevent the myosin heads from 
stably binding to actin. Most myosin heads have ATP or adenosine diphosphate (ADP) and 
orthophosphate (Pi) bound [5]. Generally, when ATP binds to the myosin head, myosin is 
detached from the thin actin filament. Hydrolysis of the ATP to ADP induces a conformational 
change at the myosin head, which then binds to a subunit of the thin filament further to the 
direction of the Z-line. Pi is released from the ATP binding site which induces a second 
conformational change back to the initial state of the myosin head thereby causing the actual 
contraction as the myosin head keeps bound to the thin filament resulting in the filaments 
being pulled past each other.  
Intracellular Ca2+ release to the sarcoplasm mediated by transverse tubular system channels 
and SR initiates muscle contraction (via the direct interaction of dihydropyridine receptors 
(DHPRs) opening the ryanodine receptors (RYRs, reviewed in [6])). Time- and voltage-
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dependent sodium and potassium channels ensure the propagation of the action potential in 
muscle similar to the one in nerve.The intracellular membrane system SR and the transverse 
tubules are key players in the Ca2+ movements controlling muscle contraction. SR actively 
pumps, sequesters and releases Ca2+ thereby initiating and terminating muscle contraction 
[7]. The electrically excitable membrane at resting potential (reversal potentials for potassium 
and sodium through the membrane) receives signals from the motor nerve. This is 
transferred to the NMJ, where action potentials (all-or-nothing signal) propagate along the 
myofiber membranes. In order to achieve a synchronous contraction the excitation spreads 
along the transverse tubular system into the depth of the fibers. When muscle contraction is 
over, calcium is pumped back to the SR and stored by calcium-buffering proteins or it is 
taken up by the mitochondria in the sarcoplasm [6].  
1.1.4. Regeneration 
Muscle tissue has an outstanding capacity for self-repair. Regenerating muscle can be 
identified histochemically according to features as basophilic cytoplasm or large dark nuclei. 
Fetal myosin isoforms as well as intermediate filament proteins desmin and vimentin are 
expressed in regenerating muscle. Along with maturation of the muscle fiber, adult myosin 
isoforms are expressed, vimentin expression is no longer visible and desmin expression is 
extenuated. As the growth of fibrous tissue in muscle after damage represents a major 
obstacle to regeneration of muscle organization, the government of collagen proliferation 
seems to be an important factor [8]. Upon injury, damaged muscle cells become necrotic and 
macrophages remove cellular debris. In the phase of regeneration, satellite cells become 
mitotically activated, replenish the pool of satellite cells and fuse either to existing myotubes 
or form new myotubes (reviewed in [9]). The fusion of satellite cells to form primary myotubes 
is independent of nerves, but as soon as secondary myotubes have to be formed innervation 
is required. If the muscle is not rapidly renervated, severe atrophy occurs [10]. In muscular 
dystrophy, cycles of degeneration and regeneration are considered a characteristic feature of 
the disease.  
The dysferlin protein plays a role in membrane repair. Since muscle fibers are subject to high 
mechanical stress, membrane damage occurs quite frequently. Dysferlin-carrying vesicles 
are then carried to the site of disruption with a high Ca2+ concentration and provide a “patch” 
for membrane repair. Mutations in the dysferlin gene lead to Myoshi myopathy (MM) or 
LGMD2B where the cause of muscle damage is a defect in mucle membrane maintenance 
rather than a structural problem like in most other muscular dystrophies [11].   
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1.1.5. Muscle proteins  
1.1.5.1. Myosin and Actin – the contractile proteins 
Myosins are a large superfamily of about 15 classes of motor proteins which interact with 
actin, hydrolyze ATP and generate cell movement [12]. As the myosin II class was 
discovered long before the other classes, it is referred to as “conventional” myosin. Members 
of myosin class II are hexameric rod-like proteins consisting of two heavy (223kDa) and four 
light chains (15-22 kDa) found in skeletal muscle cells as well as in non-muscle cells. Both 
the heavy chains form filaments by assembling a rod-like coiled-coil domain with two light 
chains attached at a globular structure at both their respective amino ends [3]. These 
globular structures do contain the ATP binding sites as well as cross bridges to establish the 
actin/myosin contact. Therefore, myosin has enzymatic (head) and structural (tail) properties. 
The myosin head accounts for about 130kDa divided in three domains with the smallest 
domain lying at the junction with the tail and associating with the light chains [3]. Myosin 
heads in vivo (in the presence of ATP and in the absence of Ca2+) are highly organized in a 
helical order, in vertebrates, the number of coaxial helices is three. Upon activation or upon 
ATP depletion, the array of the heads gets disordered. 
In adult mammalian skeletal muscle, four MHC isoforms are known: the “slow” β-MHC 
(MHCIβ), and the “fast” IIa-, IIb-, and IIx-MHC. Major myosin light chain (MLC) isoforms in 
mammalian skeletal muscle are the “slow” MLC1s and the “fast” MLC1f and MLC3f [13, 14]. 
The MHC isoform profiles may serve to classify muscle fibers into either pure fiber types or 
so-called hybrid fiber types containing a specific combination of MHCs [14]. Such fiber-type 
patterns of expression are seen as well for MLCs and other muscle proteins such as α-
actinin, troponin, various Ca2+-regulatory proteins and others [14]. Myosin forming the thick 
myofibrillar filament accounts for about 54 percent of myofibrillar protein [3].  
In normal muscle fibers there is little co-expression of slow and fast myosin isoforms 
whereas in dystrophic muscle, co-expression of slow, fast and fetal myosin can occur in the 
very same muscle fiber indicating some extent of abnormality [15].  
 
Actin is a globular protein (G-actin, molecular mass 42 kDa) self-associating to the thin 
myofibrillar filament (F-actin) and accounting for 20 percent of myofibrillar total protein [3]. F-
actin filaments are built up from two strands of actin subunits twisted around each other 
forming a double helix with one turn of each helix containing 13-14 actin subunits. Major 
differences in sequence between skeletal, cardiac, smooth muscle and nonmuscle actins are 
found near the N-terminus and polymers from sarcomeric actins are stabler than those from 
cytoskeletal actins [3].  
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1.1.5.2. The dystrophin-glycoprotein complex (DGC) 
The DGC was first purified from rabbit skeletal muscle membranes in 1990 by Kevin 
Campbell and co-workers [16]. Four wheat-germ agglutinin-binding proteins with molecular 
weights (MW) of 156kDa (α-dystroglycan), 50kDa (α-sarcoglycan), 43kDa and 35kDa were 
shown to co-purify with dystrophin. The DGC provides a structural link between the 
cytoskeleton and the ECM, but also has an important role as a receiver and transducer of 
cell signals [6]. It contains extracellular proteins (α-dystroglycan), cytoplasmic proteins 
(syntrophins, dystobrevins), and transmembrane proteins (sarcoglycans, β-dystroglycan, 
sarcospans, see Figure 2). Other associated proteins are caveolin-3 and neuronal nitric 
oxide synthase (nNOS). These proteins are expressed along the sarcolemmal membrane 
and therefore also at the NMJ and the MTJ. Other proteins such as utrophin, dystrobrevin-1, 
β2-syntropin, and unique laminin forms in contrast are exclusively expressed at the NMJ (for 
a review see [17]).  
 
 
Figure 2: Dystrophin-glycoprotein complex. Figure taken from Emery, A.E.H, BMJ 1998 [18].  
 
 
1.1.5.3. Dystrophin 
In 1987, the dystrophin protein was shown to be the protein product of the DMD gene by 
Hoffman et al. [19]. Dystrophin in skeletal muscle (tissue-specific isoforms are known) is a 
large subsarcolemmal cytoskeletal protein [20]. The large cytoskeletal protein associates 
tightly with sarcolemmal glycoproteins through its carboxy-terminal domain and binds F-actin 
through its amino-terminal domain thereby anchoring the sarcolemma to the cytoskeleton of 
the muscle cell (reviewed in [21, 22]). Disruption of this link caused by the absence of 
dystrophin renders the sarcolemma susceptible to damage after muscle contraction and 
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results in necrosis.  The actin-binding amino-terminal domain (exons 1-8) is highly similar to 
the actin-binding domains of spectrin or α-actinin. The rod-like domain (exons 9-62, also 
called triple-helical-repeat domain) accounts for most of the molecular mass of dystrophin 
and resembles the rod-like domains of spectrin and α-actinin. However, dystrophin forms a 
rather “nested” structure and unlike spectrin residues, not an antiparallel dimer (due to the 
lack of outer hydrophobic residues). The cysteine-rich domain (exons 63-69) shows high 
homology to the C-terminus of α-actinin, its N-terminus forms together with the C-terminus of 
the rod-like domain the site of a WW domain required for the binding to β-dystroglycan. The 
highly conserved across species C-terminal domain of the dystrophin protein (exons 70-79) 
has two α-helical coiled-coil domains similar to utrophin and binds to dystrobrevin (reviewed 
in [22]). The tight membrane association of dystrophin is mediated through the dystrophin-
associated protein complex (DAP) and dystrophin is linked to the ECM via the dystroglycan 
complex.  
Dystrophin is missing in DMD and often reduced in BMD patients. As in DMD, dystrophin is 
often completely absent and/or lacks the carboxy-terminus and in BMD the carboxy-terminus 
is often preserved, antibodies that are specific for the C-terminus of dystrophin are 
particularly useful for the immunohistochemical (IHC) distinction of DMD and BMD. The 
amino- and the carboxyterminus seem to be particularly important for dystrophin function as 
mutations in these regions usually lead to a more severe phenotype [23].  
 
1.1.5.4. Sarcoglycans and Dystroglycans 
Dystroglycan α- and β-subunits are encoded by a single mRNA and posttranslationally 
cleaved [24]. α-dystroglycan is a highly glycosylated ECM protein of 156kDa found by 
Campbell and co-workers in 1990 along with the discovery of the DGC [16]. It links laminin in 
the ECM and dystrophin (via β-dystroglycan). Brancaccio et al. showed a dumbbell-shaped 
structure of chick α-dystroglycan with globular domains at the N-terminus and the C-
terminus, and a mucin-like motif in the cental region [25]. Α-dystroglycan contains several N-
linked glycans [26] and extensive O-linked glycosylation in the mucin region [25]. Therefore, 
it is difficult to analyze using SDS-PAGE as glycosylated proteins often migrate as smeared 
bands in the gel. β-dystroglycan is a transmembrane protein linking the sarcolemma to intra- 
and extracellular structures [27]. Expression of β-dystroglycan seems to parallel the 
expression of dystrophin and shows a uniform and strong expression pattern where a 
“complete” dystrophin protein is expected (such as in healthy muscle or in revertant fibers in 
BMD or DMD patients) [28].  
 
α-, β-, γ-, and δ-sarcoglycan in skeletal muscle form a transmembrane complex at the 
sarcolemma with a role in sarcolemmal stability and probably involved in cell signaling upon 
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mechanical perturbations [29]. Defects in sarcoglycans are the cause of various LGMDs and 
alternatively named sarcoglycanopathies. Identical mutations do not necessarily lead to the 
same severity of the disease [1]. α-sarcoglycan is a 50kDa dystrophin-associated membrane 
glycoprotein found by Campbell and co-workers in 1990 after the description of the DGC 
[16], and originally named 50DAG. At the time, a (secondary) α-sarcoglycan deficiency in 
muscle from mdx mice could not be demonstrated due to antibodies with low affinity [16]. In 
1992, Matsumura et al. found an α-sarcoglycan deficiency in SCARMD patients [30], later 
this was demonstrated to be a secondary deficiency by linkage analyses when SCARMD 
was linked to chromosome 13 and  the α-sarcoglycan gene was mapped to chromosome 17 
[31] with several mutations causing primary deficiencies in α-sarcoglycan (LGMD2D, primary 
adhalinopathy) [31, 32]. Deficiencies in the other sarcoglycans lead to LGMD2E (β-
sarcoglycan), LGMD2F (δ-sarcoglycan) and LGMD2C (γ-sarcoglycan). Other sarcoglycans 
found in smooth muscle are ε- and ζ-sarcoglycan [33].  
1.1.5.5. Other Muscle Proteins 
 
Utrophin 
The 395kDa utrophin (dystrophin related protein, DRP) is structurally and functionally similar 
to dystrophin. The N-terminal amino acid sequence is highly conserved between DRP and 
dystrophin, and DRP also binds F-actin in vitro although with a higher affinity for nonmuscle 
actin. The expression pattern in vivo varies greatly. DRP is expressed in myoblasts during 
development [34], and in adult striated muscle becomes restricted to satellite cells, the NMJ 
and the MTJ (reviewed in [22]). Utrophin is expressed at higher levels in DMD patients 
independently of regenerating fibers [35, 36]. It has been hypothesized that utrophin could 
compensate for the missing dystrophin in DMD patients, and methods to induce utrophin 
upregulation have been suggested as therapeutic approaches to the cure of DMD. But even 
though in DMD and BMD patients a greater proportion of muscle fibers is labelled with 
utrophin antibody, β-dystroglycan does not seem to be incorporarted stably in the 
sarcolemma, suggesting that utrophin is not able to fully compensate for the lack of 
dystrophin in these patients [28].  
 
Calpain-3 
Calpain-3 is the muscle-specific member of the calpains (intracellular cysteine proteases). 
Calpain-3 is localized near Z-lines in sarcomeres and interacts with titin filaments [1]. 
Mutations in the calpain-3 gene normally cause absence or reduction in calpain-3 protein and 
LGMD2A [1], but it has been shown that a considerable number of patients show normal 
levels of non-functional calpain-3 indistinguishable from controls on Western blots [37]. The 
proteolytic activity of calpain-3 induces actin cytoskeleton and focal adhesion (subcellular 
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macromolecules that mediate regulatory effects such as cell anchorage of ECM adhesion on 
cell behaviour) disorganization. While the ubiquitous calpains (m-calpain and µ-calpain) are 
heterodimers of a large and a small subunit, calpain-3 shows similar structures to the large 
subunit of these calpains and carries specific additional sequences (insertion sequences, IS). 
IS1 contains the autolytic sites and IS2 carries a nuclear translocation signal and a titin-
binding site. Autolysis in the catalytic site (IS1) is necessary for calpain function as was 
demonstrated in [38] by expressing calpain-3 isoforms with spliced out exon 6 (containing 
two autolytic sites) and Capn3Y274A, an isoform that is unable to be processed. Rather than 
forming a heterodimer with the small subunits of other calpains, calpain-3 forms a 
homodimer through its penta-EF-hand domain (protein domain IV) [39] . EF-hands are 
common calcium-binding motifs (helix-loop-helix). Other authors state that IS1 and IS2 are 
both essential for calpain-3 autolysis [40]. 
Autolysis of calpain-3 leads to the generation of a 34kDa N-terminal fragment and a 55-
60kDa C-terminal fragment. The authors of [38] could not find specialized functions for these 
fragments, as all the fragments (34kDa, 55kDa, and 60kDa) induced normal cell spreading 
and stress fiber formation when expressed alone or in combinations in mouse myoblast cells.  
When enzymatically inactive (C129S) calpain-3 is purified, it elutes from columns at times 
corresponding to a  MW of 180kDa, suggesting that it is forming a dimer in skeletal muscle 
[40].  
 
α-actinin 
α-actinin (ACTN) is an evolutionarily conserved F-actin crosslinking protein anchoring actin to 
intracellular structures that in humans is present in at least four isoforms encoded by distinct 
genes. ACTNs are major components of the cytoskeleton and are present in many cell types 
as homodimers mainly localized along actin-containing microfilament bundles, whereas the 
skeletal muscle isoforms ACTN2 and ACTN3 localized at the Z-disk can form homo- or 
heterodimers [41]. ACTN2 is found in skeletal and cardiac muscle and ACTN3 is skeletal 
muscle specific [42]. Generally, α-actinins have an important role in the organization of 
microfilament bundles, in anchoring actin filaments specific sites within the cell, and in 
assembling microfilaments in cell-cell contact areas [41, 43] .The skeletal muscle α-actinin 
isoforms are involved in anchoring myofibrillar actin thin filaments to the Z-disk and arranging 
the them in a lateral array [3, 41].  
 
Emerin 
Emerin is a 34kDa nuclear membrane protein found in skeletal and cardiac muscle as well as 
in a range of other tissues [44, 45]. Mutations in the STA gene lead to Emery-Dreifuss 
muscular dystrophy (EDMD). Manilal et al. [45] reported emerin staining only at the nuclear 
membrane (using a panel of 12 antibodies) in all tissues tested. They furthermore found 
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emerin staining in EDMD nuclei not to be reduced only in myofiber nuclei but also in nuclei of 
blood vessel smooth muscles.  
Emerin absence in immunostainings is assumed to be specific for EDMD [46].  
 
FKRP (fukutin-related protein) 
FKRP function is still unclear. In intact skeletal muscle it is localized at the sarcolemma and 
seems to have a direct interaction with α-dystroglycan [47]. Co-enrichment and co-
sedimentation with dystroglycan, but not with dystrophin or sarcoglycans, have been shown 
[47]. Mutations in the FKRP cause congenital muscular dystrophy type 1C (MDC1C) [48] and 
its allelic disorder LGMD2I [49, 50] and are associated with a wide clinical spectrum [51]. 
MDC1C (onset in the first weeks of life) is clinically characterized by severe weakness of the 
muscles of the shoulder girdle, hypertrophy of leg (calf and thigh), and severe respiratory 
involvement that leads to respiratory failure in the second life decade [48]. Brain structure 
and intelligence are usually normal, cardiac muscle on the other hand seems to be involved, 
as several patients show signs of heart involvement [48]. A severe reduction in α-
dystroglycan immunolabelling and an inconclusive reduction in laminin-α2 immunolabelling 
are additional features of MDC1C, Brockington et al. [48] conclude from IHC findings that the 
reduction in laminin-α2 is probably the secondary reduction. General basement membrane 
organization doesn’t seem to be globally perturbed as the expression of perlecan is 
preserved [48]. FKRP appears to be directly involved in α-dystroglycan glycosylation, as 
other components of the DGC still are normally glycosylated in MDC1C patients. The onset 
of LGMD2I takes place much later than MDC1C with variable phenotypes ranging from 
relatively mild to DMD-like [50].   
1.1.6. Muscular Dystrophy 
Diseases of skeletal muscle are characterized by atrophy, weakness and paralysis and are 
considered a field of neurology. Muscular dystrophies (MD) are a clinically and 
pathogenically very heterogenous group of genetically determined myopathies varying in age 
of onset, involved muscles, and severity of the disease that lead to progressive primary 
degeneration of muscle fibers. It was recognized quite early (end of the 19th century) that the 
progressive muscular dystrophies, a term that was established by Wilhelm Erb, do differ from 
progressive muscular atrophies by concurrence of hypertrophy and atrophy (abnormalities of 
muscle fiber diameter) [1]. In all muscular dystrophies muscle fibers are lost slowly but 
gradually. This is particularly severe in DMD. As the muscle fibers disappear they are 
replaced by either perimysial or endomysial connective tissue depending on the nature of the 
myopathic disorder and on the severity of muscle fiber loss [8]. Inflammation is seen in 
various types of myositis, in muscle abscesses, vasculitis, polyarteritis nodosa and other 
muscle disorders. Inflammatory cells are also detected around and within necrotic muscle 
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fibers (macrophages), sometimes even in non-necrotic muscle fibers (lymphoid cells, in 
fewer cases macrophages) [8].  
Even though DMD is considered a non-inflammatory myopathy, some nonnecrotic muscle 
fibers are invaded by lymphocytes and macrophages (reviewed in [8]).  
Necrosis occurs in muscles upon various pathogenic stimuli and results in the injury of all 
organelles in a muscle fiber or to a segment of a fiber. In segmental necrosis contractile 
substance of a sarcomere is homogenized and the striation is destroyed. The sarcolemma is 
no longer visible and fiber contents are normally removed by phagocytes while the remaining 
fiber may survive and appear normal [8]. Complement activation is seen during muscle fiber 
necrosis.  
The classification of muscular dystrophy is an ongoing process. Classification according to 
clinical features does not necessarily reflect the underlying pathogenetical aspects and, on 
the other hand, classification according to mutation can also be misleading in cases where 
mutations in one gene can result in different phenotypes (e.g. mutations in the dysferlin gene 
causing LGMD2B or Miyoshi myopathy [1]).  
1.1.6.1. Forms of muscular dystrophies 
All muscular dystrophies lead to genetically determined muscle weakness and muscle 
wasting, which is probably the only common feature of the disease category that has a wide 
range of clinical presentations, other tissues that are affected, and involved genes and 
proteins [52]. Forms of muscular dystrophy include the Duchenne/Becker type muscular 
dystrophy (DMD/BMD), the congenital muscular dystrophies (CMD), the Emery-Dreifuss 
syndrome, the facioscapulohumeral muscular dystrophy, the oculopharyngeal muscular 
dystrophy, the large group of limb-girdle muscular dystrophies (LGMDs), distal muscular 
dystrophy and myotonic dystrophy. The incidence for the x-linked DMD is particularly high 
with 1:3500 (males), for its allelic milder form BMD  it is around ~3:100’000 [1, 53], for 
congenital muscular dystrophies: 1:20’000-1:50’000 (estimate from Leiden Muscular 
Dystrophy, http://www.dmd.nl, accessed in March 2010), for facioscapulohumeral muscular 
dystrophy: 1:20’000-1:400’000, for oculopharyngeal muscular dystrophy: around 1:200’000 in 
France (more common in Canada, 1:1000 in the region of Quebec).  
The LGMDs often have similar clinical characteristics such as paresis (weakness) and 
atrophy of muscles of the shoulder girdle and pelvis with a manifestation from the first years 
of age to the second decade, rarely later [1]. In general, the progress of autosomal-dominant 
forms (LGMD1) is slower and the prognosis is better than for autosomal-recessive forms 
(LGMD2). LGMDs do normally not progress very fast but some cases with drastically 
reduced life expectancy similar do DMD patients have been described [1]. Serum CK is 
elevated 30-100 times in autosomal-recessive forms and only slightly (in single cases up to 
25fold) in autosomal-dominant forms [1]. Sarcoglycanopathies vary considerably in disease 
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severity. LGMD2C and LGMD2F but also LGMD2D can show severities similar to DMD and 
cardiac involvement has been found in all sarcoglycanopathies [1]. In contrast to the other 
muscular dystrophies, where the molecular cause of the disease is an absence or a 
reduction in a protein, some forms of surplus protein with an excess of the relevant proteins 
are known. In the two forms of desmin-associated myopathies, the primary desminopathy 
with a mutation in the desmin gene and the α-B-crystallinopathy with a mutation in the gene 
encoding for α-B-crystallin, an accumulation of desmin is seen in the muscle cell [1].  
1.1.6.2. DMD/BMD 
The clinical spectrum of dystrophinopathies is very broad due to the high number of possible 
mutations in the large dystrophin gene. In addition to the major allelic disorders DMD and 
BMD, other phenotypes are known such as cardiomyopathy with mild muscle weakness, 
myalgias, fatal X-linked dilated cardiomyopathy and others [22]. Very likely, DMD was first 
described in the first half of the nineteenth century. Duchenne’s observations were published 
in 1861.  
Diagnosis of DMD in boys is often made before the patient is 6 years old. Motoric 
development seems to be slow and children may appear clumsy with a waddling gait 
(Trendelenburg’s sign). Running or climbing stairs becomes difficult and boys show a 
characteristic behaviour holding on to their own thighs when standing up (Gowers-Sign). 
Shoulder-girdle involvement becomes apparent early due to weakness of the torso and distal 
extremities with protruding shoulder blades. Atrophies and weakness (pareses) are often 
symmetrical, and facial muscles normally are not involved. Serum CK is significantly 
elevated, often >1000 units/L already at birth [54]. Contractures are frequent (e.g. in M. 
tibialis posterior [1]), hypertrophy is often seen in the early stadiums of DMD (especially in 
calves, muscles of the tongue, M. deltoideus and M. quadriceps femoris) [55], and muscle 
reflexes are weak or can no longer be triggered (except for the Achilles tendon reflex which 
can be preserved after the 10th year of life). Cardiac involvement is very frequent (near 100% 
in patients over 18 years of age) but there is no apparent correlation between the severity of 
the muscle disease and the severity of heart involvement. Cardiac symptoms are manifested 
in only about 50% of the patients over 18, most probably due to low heart stress because of 
low activity of the patients. Pulmonary problems are mostly the cause of death in DMD 
patients while cardiac problems account for only about 10% of deaths. Intelligence may be 
lowered in DMD patients. Prognosis for DMD patients is a chronic progressive course of the 
disease with a possible phase of recovery in the pre-school age, most possibly due to a 
discrepancy between muscle growth and dystrophic processes [1].  
BMD is characterized by a later onset of the disease and a more benign course with a higher 
life expectancy showing initial symptoms in the pelvic girdle and later in the shoulder girdle. 
BMD phenotypes vary considerably with a mild course when the deleted region of the protein 
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is in the middle region whereas deletions causing changes in the N-terminal region of the 
dystrophin protein cause severe phenotypes with an early walking disability. Defects in the 
proximal rod-like domain often cause stronger myalgia and muscle cramps and distal defects 
cause an intermediate phenotype. Nonsense-mutations of exons 30, 44 and 74 lead to 
intermediate phenotypes between DMD and BMD. Cardiac involvement is seen in over 50% 
of BMD cases and serum CK is elevated about 10-50 fold compared to controls [1].  
Female carriers do show in about 10% of the cases (mild) clinical manifestations such as calf 
hypertrophy, myalgia or mild weakness and atrophy in the pelvis- and shoulder-girdle, 
sometimes even cardiac involvement. In very rare cases a DMD phenotype is seen in 
females, when both X-chromosomes show a mutation in the region of Xp21, the patients 
suffer from the Turner-syndrome (only one functional X-chromosome), an X-autosomal 
translocation, often with an inactivation of the X-chromosome or in very few cases due to 
failure of inactivation of the maternal X-chromosome [22]. Serum CK is elevated in about 
95% of the female carriers. Overall dystrophin deficiency in DMD carriers is usually mild, and 
immunohistochemically female carriers often show a mosaic-like pattern of dystrophin-
positive and -negative fibers [1, 8].  
1.1.6.3. Molecular cause of DMD 
Even before the dystrophin gene was discovered, elevated intracellular free Ca2+ levels were 
found in  DMD patients (reviewed in [6]). Damage of the sarcolemma leads to excessive 
intracellular Ca2+ having two effects in the opposite direction: activation of the dysferlin 
membrane repair system which is desirable, but also activation of proteases (calpains), 
increased reactive oxygen species, and disturbed mitochondrial function (reviewed in [6, 9]). 
Experiments on the subproteome of  Ca2+-binding binding proteins have shown strong 
evidence for calcium dysregulation being a key factor in the pathophysiology of muscular 
dystrophies [9, 56]. Two hypotheses on how the absence of dystrophin ultimately leads to 
myofiber death exist: The structural hypothesis says that dystrophin provides a mechanical 
link between the ECM and the actin cytoskeleton and hence its absence causes instability of 
the sarcolemma and susceptibility during muscle contraction whereas the signaling 
hypothesis suggests disturbed cellular signaling in muscle cells due to dystrophin absence, 
which is the cause for muscle damage [52]. The expression of a short form of dystrophin 
(Dp116) lacking the N-terminus and most of the rod-like domain but with the WW-domain 
interacting with β-dystroglycan in mdx mice did not improve the dystrophic phenotype [57]. 
The authors suggested therefore that even though non-structural functions of dystrophin and 
DGC proteins were likely because of the ubiquitous expression of isoforms of these proteins, 
a mechanically functional dystrophin would be necessary in order to avoid a dystrophic 
phenotype.  
 21 
Absence or reduction of dystrophin protein causes secondary reductions in sarcoglycans and 
dystroglycans [58] and this disintegration of the DGC initially triggers the pathogenesis of 
DMD. Subsequent secondary substantial alterations of energy metabolism, cellular signaling 
and ion homeostasis regulation are the likely key factors causing muscle fiber death. 
Decreased rates of mitochondrial oxidative phosphorylation rates and a substantial alteration 
of mitochondrial protein composition were observed in quadriceps muscle fibers of mdx mice 
which were not found in cardiac muscle or regenerating fibers [59]. Mitochondrial protein 
composition showed drastically decreased hemoproteins in mitochondria, which leads to 
elevated steady state redox states of the mitochondrial NAD-system that were observed in 
quadriceps muscle fibers of mdx mice but not in cardiac muscle or regenerating fibers [59]  
The lowered activity of respiratory chain-linked enzymes and the decreased rates of 
mitochondrial respiration are evidence for an inhibition of the respiratory chain. Oxidative 
stress has been shown to be enhanced in mdx mice where nNOS that normally produces NO 
reacting with free radicals is reduced. Absence of nNOS can however not be the only reason 
for oxidative stress causing muscle degeneration in mdx mice as mice lacking nNOS present 
normal muscle architecture (reviewed in [9]). The series of degeneration-regeneration events 
in DMD is presumably described the following way: rupture of the myofiber plasmalemma 
leads to the influx of extracellular calcium (probably causing hypercontraction) causing the 
myofiber to undergo necrosis (and autodigestion by proteases). The endomysial tube 
composed of the basal and reticular laminae often survives injury. After macrophages 
removed the cell debris satellite cells enter the cell cycle, start to proliferate, and form a 
“seal” of tissue at the inner surface of the basal lamina. When the satellite cells withdraw 
from the cell cycle they fuse to multinucleated myotubes (partly with the remaining myotubes 
from before the injury) and the original pool of satellite cells is restored [10]. An altered 
distribution of the dysferlin protein which is not an integral component of the DGC has been 
shown in DMD patients suggesting the dysferlin function that is crucial for membrane repair 
in muscle cells is affected in DMD [11].  
1.1.6.4. Therapeutic approaches 
Even though the genes and proteins involved in DMD have been known more than 20 years, 
no effective and lasting cure has been found that is applied routinely in humans. The large 
size of the gene and its expression in all muscles except brain have so far obstructed the 
development of an effective treatment [60]. Therefore, current therapeutic approaches focus 
on symptomatic therapies such as the administration of glucocorticoids in order to slow down 
muscle wasting, the administration of β-blockers in order to prevent heart failure, physical 
therapies for the improvement of muscular function, and non-invasive ventilation [54]. 
Current research activities include gene-replacement strategies using adeno-associated viral 
vectors, antisense-oligonucleotides to induce exon skipping for the restoration of a milder 
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phenotype, and read-through stop codon agents such as PTC124 are promising approaches 
(reviewed in [60]). Antisense-oligonucleotides have been shown to restore dystrophin 
expression to levels from 3-12% [61] to >25% in humans [62] as well as to ameliorate 
secondary pathobiochemical abnormalities [63] and clinical trials are currently going on [60].  
1.1.6.5. Current Diagnosis 
For most of the muscular dystrophies the affected genes and their protein products are 
known [64, 65]. Current methods for differential diagnosis of muscular dystrophies include 
clinical examinations, genetic analyses, the measurement of serum CK, electromyography, 
the histological analysis of variations in muscle fiber size, necrosis and increased amounts of 
fat and connective tissue as well as the IHC analysis of muscle using a wide range of 
antibodies [64, 65]. Besides CK, other muscle-specific enzymes such as pyruvate kinase, 
aldolase, alanine aminotransferase, aspartate aminotransferase, and l-lactate 
dehydrogenase are found in serum in higher concentrations compared to controls [1]. The 
increases in CK and myoglobin in serum are more marked in DMD patients than in other 
forms of muscular dystrophies [1].  
In DMD patients, besides the considerable variation in muscle fiber size, degeneration of 
fibers, hypertrophic and atrophic fibers, decentralized nuclei, connective tissue and fat 
deposits are seen in muscle histology [1]. In immunolabelings of proteins it is of importance 
to distinguish primary deficiencies from secondary deficiencies as generalized membrane 
damage and the resulting loss in membrane proteins is a common feature of dystrophic 
muscle [48]. Regenerating fibers seen in dystrophic muscle in immunocytochemical analyses 
often show low levels of β-spectrin and α7-integrin but increased expression of utrophin, 
laminin-α5 and MHC class I antigens [15]. These regenerating fibers can be visualized by 
labelling with an antibody against fetal myosin. Moreover, in more than 50% of all DMD 
patients, single dystrophin-positive fibers are found in IHC [1, 66], referred to as revertant 
fibers where probably the reading frame has been restored [67]. In DMD carriers even 
though immunocytochemistry is more sensitive than Western blot analysis, it may not be 
diagnostic in some cases (reviewed in [8]). 
A reliable diagnosis of DMD or BMD is not always possible based on clinical examination 
and genetic analysis. The detection of deletions and duplications in the large dystrophin gene 
is comparatively straightforward using direct DNA testing (multiplex PCR, MLPA), however, 
about one third of all mutations in the dystrophin gene are small mutations, which are more 
challenging to identify. Sequencing of the large dystrophin gene (79 exons) is time- and cost-
intensive. Even with today’s methods for the automated detection of point mutations which 
are being established [68, 69], the percentage of identified mutations in all patients remains 
around 90% [53, 70, 71]. Genotype-phenotype correlation predictions in DMD/BMD patients 
are challenging [53, 71]. The reading frame hypothesis predicting severe DMD phenotypes 
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for mutations which disrupt the reading frame and milder BMD phenotypes for mutations 
which maintain it [72] holds true in about 90% of the cases, but even in patients with the 
same mutation phenotypic variability was found [53]. Due to these ranges in variability, in 
cases of suspected DMD/BMD muscular dystrophy, a muscle biopsy is often taken for 
diagnostic purposes for subsequent molecular analysis using Western blot techniques and/or 
IHC. With an informed consent of the patient to participate in a research project muscle 
biopsies are sometimes taken after a definitive diagnosis for research purposes. The same 
approach is used for LGMDs. Even though most of the genes affected in the diseases are 
known, a diagnosis based exclusively on genetic testing is usually not suitable due to low 
efficiency as well as high costs, and a muscle biopsy remains the gold standard method for 
LGMD testing [73].  
Even though the risk associated with a muscle biopsy is generally minimal, it causes 
discomfort to the patient and therefore has to be carried out in a way to optimize the 
usefulness while minimizing pain and inconveniences. Various muscles can be chosen for 
the muscle biopsy. Gastrocnemius muscle is subject to a heavy workload and can therefore 
show myopathic alterations due to denervation atrophy [74]. Severely affected muscles are 
usually not biopsied because of the replacement of muscle tissue by fibrous and fatty 
connective tissue. Also the muscle should be free from previous trauma (such as a 
precedent muscle biopsy) that could alter histological findings. If they are not too severely 
affected, triceps or biceps muscle of the upper extremity or vastus lateralis are often suitable 
for diagnostic muscle biopsies. In any case, it must always be kept in mind that muscle fibers 
may have very distinct histochemical profiles according to their innervation and fiber type 
distributions that vary considerably between muscles. The four fiber types in muscle can be 
determined by the pH-sensitive ATP reactions at different pHs on cryostat sections (unfixed 
frozen muscle). Type 1 fibers are base-labile and acid-stabile with the opposite being true in 
type-2 fibers. Type 2B and type C (infrequent in human muscle) can further be distinguished 
by their activity over a wider pH range than type 2A fibers [8].  
All muscle fibers of one motor unit are of the same fiber type and the typical mosaic 
“checkerboard” pattern is the result of the intermingling assembly of fibers of different types. 
As differentiation into the mosaic pattern starts step by step after the 22nd week of fetal life, 
before the 30th week, the myofibrillar ATPase reactions stain all fibers equally dark 
regardless of pH or incubation time because the fibers are still undifferentiated or type 2C 
fibers. In humans, in anterior tibial and deltoid muscles, type 1 fibers are more abundant 
whereas in vastus medialis or soleus muscles, type 2 fibers can be more abundant in 
superficial than in deeper muscle regions [74]. These natural predominances of fiber types 
always have to be taken into consideration when assessing fiber types in muscle and protein 
alterations that could be altered depending on the analyzed fiber type.  
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Another complicating feature of muscular dystrophy protein diagnostics are secondary 
protein deficiencies [65, 73]. In DMD/BMD patients, the absence or reduction of dystrophin is 
often coupled with secondary deficiencies in proteins of the DGC [55]. Primary absence of 
one of the sarcoglycans can be coupled with secondary reductions in dystrophin and/or in 
the other sarcoglycans of such variable extent that the application of one sarcoglycan 
antibody is not sufficient to discriminate sarcoglycanopathies from other muscular 
dystrophies [75]. In some cases primary dysferlinopathies (LGMD2B) have been reported to 
be associated with secondary calpain-3 deficiencies [76], the muscle-specific protease that is 
reduced in LGMD2A.  
In conclusion, when diagnosing muscular dystrophies and when assessing protein levels in 
muscle biopsies, antibodies to a large panel of proteins are routinely used making biopsy 
sample size critical also in terms of discomfort for the patient. 
1.1.7. Satellite cells and muscle cell culture 
Satellite cells are quiescent myoblastic stem cells that are localized at muscle fiber surface 
inside the basal lamina [10]. During their early development they proliferate and then 
withdraw from the cell cycle. Satellite cells contain all organelles but no myofibrils and are 
delimited by a plasma membrane. About 5% of all nuclei in adult muscle depending on the 
muscle type, age, and species account for satellite cells, postnatally about 30%, while at the 
NMJ, these numbers are markedly higher [10]. Moreover, slow-twitch muscles contain more 
satellite cells than fast-twitch muscles. Satellite cells play an important role in muscle growth 
after exercise, hypertrophy, and regeneration after injury. Resting satellite cells in the muscle 
are activated upon muscle fiber damage, exercise, denervation, stretching, and overuse. The 
degeneration-regeneration cycles in DMD include extensive satellite cell proliferation [10].  
They are a heterogenous population with a small fraction of cells possessing stem cell 
properties [8, 10].  Early myogenic cell populations can be distinguished by their expression 
of muscle-specific proteins such as H36 or desmin. In addition to the satellite cells, 
mononucleated stem cells with a higher plasticity that are capable of proliferation and 
differentiation are found at lower numbers in muscle. The restricted lineage of these cells 
includes myoblast, fibroblast, chondroblast, osteoblast and adipocytes and interconversions 
can occur. In addition, stem cells originating from other tissue (particularly bone marrow) can 
have myogenic potential [10]. This effect is only seen after muscle damage though (and the 
cells having myogenic potential share the surface marker CD34 with satellite cells). Although 
the basal lamina is often considered a barrier for cell migration satellite cells are probably 
capable of crossing it in both directions e.g. upon muscle injury (probably in young tissue 
rather than in adult tissue as the basal lamina thickens with age), which makes myoblast 
transfer another interesting approach for therapies in various muscle diseases [10], however, 
there have been numerous failures and limitations to its application (reviewed in [77]). In 
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order to get activated for proliferation the quiescent satellite cells need at least a competence 
factor to enter the G1 phase of the cell cycle and a progression factor to stimulate the cells to 
undergo the rest of the cell cycle including mitosis. Fibroblast growth factors (FGF) stimulate 
the proliferation of fibroblasts and in serum-free media, the proliferation of satellite cells, but 
inhibit the differentiation of satellite cells. Interestingly, the levels of FGF have been found to 
be elevated in mdx muscle and after injury, indicating that FGF might be released from the 
basal lamina in mature muscle upon muscle damage [10]. Insulin-like growth factors (IGF), 
on the other hand, have been suggested to act as progression factors stimulating cell 
proliferation during development (enhanced by dexamethasone which suppresses the 
production of IGF-binding protein and elevates IGF-receptors in myogenic cell lines), but only 
when the cells have already entered the cell cycle. The combination IGF/FGF stimulates the 
proliferation of myoblasts in cell culture. Other factors are known to inhibit satellite cell 
differentiation such as transforming growth factor β (TGFβ). During the process of 
myogenesis large rearrangements of the proteome in muscle cells take place [78]. 
As skeletal muscle tissue is difficult to obtain for research purposes primary human muscle 
cell cultures could provide a (limited) renewable source of samples. Primary human muscle 
cells can be cultivated as myoblasts and differentiated in vitro into myotubes. Satellite cells 
are extracted from human muscle biopsies by enzymes (trypsin, pronase) dissolving the 
basal lamina and stimulated to proliferate using a range of growth factors [10]. In contrast to 
cell lines they have no unlimited lifespan as the ability of myoblasts to divide declines with 
every passage [79]. About 25-30 cell doublings can be reached in culture from adult muscle 
and around 60-70 doublings in cell cultures obtained from fetal muscle [10]. Satellite cells 
extracted from DMD muscle tissue do not have the same potential of in vitro doubling as 
those from healthy subjects indicating that satellite cells in the patients may be in a more 
senescent proliferative stage [9, 10]. Generally, cells extracted from neonatal muscle 
proliferate much earlier in culture than those extracted from human muscle which undergoes 
a long lag phase [10]. In the absence of mitogenic stimuli that come from serum in tissue 
culture myoblasts withdraw from the cell cycle elongate and fuse to multinucleated myotubes 
appearing morphologically very different from myoblasts (see see Figure 3 for an example of 
C2C12 mouse myoblast cell line). As myoblasts in tissue culture start to differentiate into 
multinucleated myotubes, dystrophin transcription is initiated [22] and other muscle-specific 
genes are expressed.  
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Figure 3: Differentiation of C2C12 mouse myoblasts in culture. After six days of differentiation, 
multinucleated myotubes are formed. The nuclei are stained with DAPI. 
 
1.1.8. Animal models 
There are several animal models for muscular dystrophies. The mdx mouse was a 
spontaneous point mutation in the dystrophin exon 23 from C57BL/10ScSn inbred mice [23, 
80] and is widely accepted as animal model for DMD even though the mice’ pathology does 
not perfectly reflect the progression of the disease in human patients. Disease progression in 
the mouse is milder than in humans, and mdx mice undergo a phase of recovery at about 2-3 
months of age that is not seen in humans. The reason for the milder disease phenotype in 
mice is not entirely clear, it has been hypothesized that other proteins compensate for the 
absence of dystrophin in the mouse or that the animals that are kept in cages in laboratories 
are not exposed to the same levels of physical stress than humans in everyday life (reviewed 
in [81]). The symptoms observed in mdx limb muscles are relatively mild whereas the mdx 
diaphragm shows severe muscle wasting like human DMD patients (reviewed in [23]). 
Therefore, a relatively high number of studies are performed on mdx diaphragm in order to 
have a more realistic model of DMD in humans [63, 82, 83]).  
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1.2. Aim of the Thesis 
 
1.2.1. Proteomic approaches and biomarker discovery 
A biomarker is a molecule or characteristic feature that can be measured and therefore 
represents an indicator of the state of health of an organism [84]. A diagnostic biomarker 
must be sensitive and specific enough so that it can be applied in a laboratory process [84]. 
Ideal biomarker properties a) soluble (! easier access), b) (relatively) abundant (! 
favourable signal-to-noise ratio), c) relatively consistent in density between control samples 
(! easy statistical evaluation), d) relatively consistent over time in control samples, e) highly 
disease-specific (so that common pathophysiological pathways between diseases do not 
lead to misdiagnosis) [85]. At best, the identification of novel biomarkers leads to the 
optimization of diagnostic processes and the detection of therapeutic targets [85]. To find 
such biomarkers has turned out to be more challenging than expected and despite the 
technical development, approvals of biomarkers by the FDA have recently been declining 
[84]. In contrast to diagnostic biomarkers, disease biomarkers present another group that 
delivers information underlying molecular mechanisms of the disease itself or its treatment 
yet do no not meet the same level of sensitivity and/or specificity [84]. Limitations of 
proteomic approaches to disease or diagnostic biomarker discovery in tissue samples 
include high sample variability and limited amount of sample [84, 86].  In 2DE, low-
concentration proteins are often obscured by highly abundant proteins, protein size range is 
limited, and there is a relatively high probability of introduction of experimental error due to 
many manually performed steps. Expression levels of proteins probably vary by several 
orders of magnitude, therefore a single 2DE experiment is only capable of presenting a 
limited part of the total proteome present in the sample [85]. In the case of skeletal muscle, 
the highly abundant proteins actin, tropomyosin, troponin as well as the heavy and light 
chains of myosin present a challenge in the 2DE separation of the tissue extract as they 
account for about 50% of a muscle fiber’s protein content and might mask other proteins of 
lower abundance. However, pre-fractionation techniques that are available might by their 
very nature introduce artefacts such as undesirable modifications to the remaining proteins 
and are therefore often not recommendable [85]. DIGE reduces gel-to-gel variation, but is 
extremely costly in terms of fluorophores and software [85].  
Despite all these limitations, proteomic profiling using either 2DE or LC methods as 
separation technique serves as a powerful tool for the fast identification of candidate 
biomarkers. Based on the data obtained in these screenings, potential novel biomarkers can 
then be studied by standard biochemical methods (matrix-assisted laser desorption 
ionisation (MALDI)-ToF MS, electrospray ionization (ESI)-MS/MS, immunoblotting, 
immunofluorescence) in order to evaluate their usefulness in diagnostic or therapeutic 
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approaches [85]. We carried out proteomic profiling in human skeletal muscle tissue from 
DMD patients compared to healthy controls as well as other muscular dystrophies in order to 
evaluate secondary pathogenic consequences of the absence of dystrophin.  
1.2.2. Microarrays 
As an increasing number of drug targets is signaling-related and proteomic approaches to 
molecular network analysis might represent a substantial progress in true patient-tailored 
therapies [86], reverse protein arrays represent an attaractive technology to this approaches 
because of the possibility of large-scale analyses as they are capable of measuring multiple 
analytes in parallel while requiring only minute amounts of samples. Protein microarrays can 
in contrast to gene microarrays monitor post-translational modifications such as for example 
phosphorylation events in the profiling of cellular signal pathways [86].  Samples are spotted 
under denaturing or non-denaturing (for the measurement of protein-protein or protein-
DNA/RNA interactions) in serial dilutions generating a certain internal standard and 
demonstrating the linear range of the measurement. If reference standard proteins are 
available, a direct and quantitative measurement of analyte concentration is possible within 
the linear dynamic range of the assay. In spotted lysates phosphorylated isoforms of low 
abundance proteins can still be detected in under 10 cell equivalents [86].  
The low sample volume, low antibody consumption and the measurement of quantitative 
signals make reverse protein arrays a cost efficient and reliable method for all applications 
where sample size is limited and quantification is required. Downscaling of the gold standard 
IHC analyses to a reverse protein array format creates the possibility to perform assays for 
markers of interest in a sample containing about 10 mg of tissue, as it can be obtained from 
a single needle biopsy or around 10 cryosections. Various assay formats have been 
established based on antigen-antibody interactions, for an overview see Figure 4. To achieve 
low limits of detection despite the extremely small sample volumes highly efficient detection 
techniques are a prerequisite. We have chosen the planar waveguide based evanescent field 
fluorescence excitation principle as provided by Zeptosens. This surface-confined analyte 
detection is highly sensitive and precise and does not require any enzymatic amplification 
steps [87]. The indirect labelling of the patient sample provides a marked improvement in 
reproducibility, sensitivity, and robustness of reverse protein arrays [86]. We show that the 
material- and time-saving method using reverse protein arrays can successfully be employed 
for the quantitative and reproducible measurement of muscle proteins in tissue samples or 
cultured primary myotubes of patients suffering from muscular dystrophy using a set of 
antibodies currently in use for the diagnosis of muscular dystrophies. 
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Figure 4: Basic principles of protein microarrays. In capture or sandwich arrays, antibodies are 
spotted on the chip surface. The arrays are then incubated with sample lysate (labelled in capture 
assays, unlabelled in sandwich assays). For sandwich assays, a second antibody recognizing the 
protein of interest is needed (if unlabelled, yet another secondary antibody is applied similar to a 
minaturized ELISA). In reverse protein arrays, the sample lysate is spotted directly onto the chip 
surface and the arrays are then incubated with primary antibodies and (if primary antibody is 
unlabelled) subsequently with a fluorescence-labelled secondary antibody.  In all assay formats shown 
here, readout is fluorescence intensity. 
 
 
 30 
2. MATERIAL AND METHODS 
 
2.1. Preparation of muscle tissue extracts 
Muscle biopsies from DMD/BMD/LGMD patients and controls (patients who showed non-
specific diagnostic findings) were provided by the muscle tissue culture collection (MTCC) at 
the Friedrich Baur Institute (FBI) of the Ludwig-Maximilians University in Munich, Germany, 
the Department of Neurology at the University of Bonn, Germany and the University Hospital 
Basel, Switzerland. Three control biopsies were a kind gift of Prof. Dr. Eric Kübler (FHNW; 
Muttenz, Switzerland). Muscle tissue (around 10 mg) was lysed in ten times volume cell lysis 
buffer (CLB1, Zeptosens) using the Labsonic ultrasonic homogenization system (3x30 sec, 
0.6 cycle length and 70% amplitude, cooled down on ice between each homogenization step 
for 30 sec). Lysates were centrifuged at room temperature at 10,000 g for two minutes and 
the supernatant was used for further analysis. Samples were stored at -80 °C if not 
processed immediately. A sample list is given in Table 1.  
2.2. Cell culture  
2.2.1. Primary cell culture 
Extraction of satellite cells from human biopsies was carried out in the laboratories of the FBI 
at the University of Munich according to protocols of the MTCC: Muscle biopsies were stored 
in solution A (30 mM HEPES pH 7.6, 130 mM NaCl, 3 mM KCl, 10 mM glucose, with a trace 
of phenol red) at 4 °C not exceeding 4 days. Biopsi es were then transferred to solution A with 
0.05% trypsin-EDTA and cut in small pieces using sterile scalpel blades. Muscle pieces were 
stirred in wheaton flasks using magnetic stir bars in solution A with trypsin-EDTA for 15min. 
Supernatants were poured in Dulbecco’s modified eagle medium (DMEM) with 10% fetal calf 
serum (FCS) and 40 µg/ml gentamicin. Stirring in Wheaton flasks and removal of the 
supernatant was repeated twice and supernatants were centrifuged at room temperature for 
10 minutes at 1200 rpm. The resulting pellets were resuspended and combined in skeletal 
muscle cell growth medium (SGM, (PromoCell) with 15% FCS, 50 µg/ml fetuin, 1 ng/ml basic 
fibroblast factor, 10 ng/ml epidermal growth factor, 10 µg/ml insulin, 0.4 µg/ml 
dexamethasone, 3 mM glutamax, and 0.03 µg/ml gentamicin). Cultures were incubated at 37 
°C and 5% CO 2. After 24 h, SGM was changed and after 72 h, cultures were rinsed twice 
with phosphate buffered saline (PBS) in order to remove cell debris. After 48 h, first 
myoblasts were usually visible.  
Myoblast cultures were expanded in SGM at 37 °C and  5% CO2, SGM was replaced every 
two to three days. Upon reaching about 70% confluence, SGM was removed and myoblasts 
were differentiated to myotubes in DMEM supplemented with 5% horse serum and 
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penicillin/streptomycin. Cells were harvested on day four or five of differentiation using ice-
cold PBS and a cell scraper. Cell suspensions were centrifuged at 4°C and 8000 rpm for four 
minutes, the supernatant was removed and cell pellets were stored at -80°C. Pellets were 
resuspended in CLB1 and lysates were centrifuged at 10,000 g for 2 minutes at room 
temperature, then stored at -80 °C until spotting. For a sample list, see Table 1. 
2.2.2. C2C12 cell culture 
The mouse myoblast cell line C2C12 (ATCC Nr. CRL-1772, strain C3H, was obtained at the 
6th passage and was a kind gift of Jasmin Althaus (FHNW, Muttenz, Switzerland). Myoblasts 
were expanded in maintenance medium (DMEM supplemented with GlutaMax (Invitrogen), 
10% FCS, and penicillin/streptomycin). Upon reaching ~70% confluence maintenance 
medium was removed and differentiation of the myoblasts to multinuclear myotubes was 
induced in DMEM supplemented with GlutaMax, 5% horse serum, and 
penicillin/streptomycin.   
2.3. Antibodies 
Mouse monoclonal antibodies against α-sarcoglycan (NCL-a-SARC), β-dystroglycan (NCL-b-
DG), β-sarcoglycan (NCL-b-SARC), calpain-3 (NCL-CALP-2C4), δ-sarcoglycan (NCL-d-
SARC), dysferlin (NCL-HAMLET), dystrophin (rod-like domain: NCL-DYS1; C-terminus: NCL-
DYS2; N-terminus: NCL-DYS3), emerin (NCL-EMERIN),  γ-sarcoglycan (NCL-g-SARC), 
spectrin (NCL-SPEC1), and utrophin (NCL-DRP2) were all purchased from Novocastra 
Laboratories (Leica Microsystems).  The monoclonal mouse antibody against α-dystroglycan 
antibody (clone VIA4-1) was obtained from Upstate (Millipore), 
Monoclonal mouse α-actinin antibody (clone EA-53, skeletal muscle isoform 3, specific for α-
skeletal and α-cardiac muscle actinins), monoclonal mouse β-tubulin antibody (clone AA2, 
reacts with β-tubulin types I, II, III, and IV), and monoclonal mouse MHC fast antibody (clone 
MY-32, reacts with fast (type II) and neonatal isomyosin molecules in skeletal muscle) were 
purchased from Sigma-Aldrich. 
The desmin antibody was purchased from DAKO and the antibody against an 80kDa 
fragment of laminin-α2 was from Chemicon (Millipore). Myosin β slow heavy chain antibody 
was from Alexis Biochemicals. The goat polyclonal FKRP antibody against the C-terminus of 
the FKRP protein and goat polyclonal heat shock protein (HSP)-β2 antibody were purchased 
from Santa Cruz Biotechnology (LabForce). The antibodies against voltage-dependent anion 
channel (VDAC) 2 (goat polyclonal and mouse monoclonal) and against glycerol-3-
phosphate dehydrogenase-like protein 1 (GPD1L) were obtained from Abcam.  
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Table 1: Sample list of muscle tissue and myoblasts spotted on for reverse protein arrays and 
analyzed in 2DE experiments. Cryosections were all in TissueTek. 
 
Sample Disease Mutation Sample State Muscle 
CONT 1 -- -- Cryosections quadriceps femoris 
CONT 2 -- -- Native Biopsy tibialis anterior 
CONT 3 -- -- Native Biopsy biceps brachii 
CONT 4 -- -- Native Biopsy deltoideus 
CONT 5 -- -- Native Biopsy tibialis anterior 
CONT 6 -- -- Native Biopsy deltoideus 
CONT 7 -- -- Native Biopsy unknown 
CONT 8 -- -- Native Biopsy unknown 
CONT 9 -- -- Native Biopsy unknown 
CONT 10 -- -- Native Biopsy tibialis anterior 
CONT 11 -- -- myoblasts unknown 
CONT 12 -- -- myoblasts unknown 
CONT 13 -- -- myoblasts unknown 
CONT 14 -- -- myoblasts unknown 
CONT 15 -- -- myoblasts unknown 
CONT 16 --  Native Biopsy unknown 
BMD 1 BMD Duplication (exon 45-49) Native Biopsy vastus lateralis 
BMD 2 BMD Deletion (exon 45) Cryosections quadriceps femoris 
BMD 3 BMD Deletion (exon 48-50) Cryosections quadriceps femoris 
BMD 4 BMD Duplication (exon 45-49) myoblasts unknown 
BMD 5 BMD unknown myoblasts unknown 
DMD 1 DMD Exon 64  9337C>T Cryosections vastus lateralis 
DMD 2 DMD Exon 40 5602-5605del Cryosections vastus lateralis 
DMD 3 DMD Duplication (exon 12-21) Cryosections vastus lateralis 
DMD 4 DMD Deletion (exon 29-43) Cryosections vastus lateralis 
DMD 5 DMD Deletion (exon 4-15) Cryosections unknown 
DMD 6 DMD* c357+2T2A, Intron 5 Cryosections vastus lateralis 
DMD 7 DMD Deletion (exon 45-52) Cryosections quadriceps femoris 
DMD 8 DMD Deletion (exon 51) Cryosections unknown 
DMD 9 DMD Deletion (exon 3-12) Native Biopsy unknown 
DMD 10 DMD Deletion (exon 56-62) Native Biopsy quadriceps femoris 
DMD 11 DMD Duplication (exon 8-29) Cryosections unknown 
DMD 12 DMD unknown Native Biopsy tibialis anterior 
DMD 13 DMD   unknown myoblasts unknown 
DMD 14 DMD  Duplication (exon 8-29) myoblasts unknown 
DMD 15 DMD unknown Cryosections unknown 
DMD 16 DMD  unknown myoblasts unknown 
DMD Carr 1 DMD Carrier unknown myoblasts unknown 
DMD Carr 2 DMD Carrier unknown myoblasts unknown 
LGMD2A 1 LGMD2A unknown Native Biopsy unknown 
LGMD2A 2 LGMD2A unknown Native Biopsy unknown 
LGMD2A 3 LGMD2A unknown Native Biopsy unknown 
LGMD2A 4 LGMD2A unknown Native Biopsy unknown 
LGMD2C 1 LGMD2C Deletion (exon 1-4)/Intron 1 -1+5G>A myoblasts unknown 
LGMD2D 1 LGMD2D unknown Native Biopsy biceps brachii 
LGMD2D 1 LGMD2D Exon 5 402C>G/Exon6 622A>G myoblasts unknown 
LGMD2D 2 LGMD2D Exon 3 229C>T/Exon 7 850C>T Native Biopsy tibialis anterior 
LGMD2D 2 LGMD2D Exon 2 100C>T/Exon 3 229 C>T myoblasts unknown 
LGMD2D 3 LGMD2D Exon 3 229C>T  Native Biopsy unknown 
LGMD2D 4 LGMD2D Exon 3 229C>T Native Biopsy tibialis anterior 
LGMD2E LGMD2E Exon 4 499G>A Native Biopsy unknown 
LGMD2I 1 LGMD2I unknown Native Biopsy quadriceps femoris 
LGMD2I 2 LGMD2I unknown Cryosections tibialis anterior 
LGMD2I 3 LGMD2I unknown Cryosections rectus femoris 
LGMD2I 4 LGMD2I unknown Native Biopsy unknown 
LGMD2I 5 LGMD2I unknown Native Biopsy unknown 
LGMD2I 6 LGMD2I unknown Native Biopsy unknown 
LGMD2I 7 LGMD2I unknown Native Biopsy unknown 
UKN 1 LGMD2A unknown Cryosections unknown 
UKN 1 unknown unknown Cryosections unknown 
UKN 2 unknown unknown Cryosections unknown 
* intermediate phenotype DMD/BMD 
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2.4. Microarrays 
2.4.1. Sample and array preparation 
Tissue or primary cell lysates for microarrays were prepared in CLB1 as described in 2.1 and 
protein content was determined using the Bradford assay using BSA as standard protein. 
Total protein concentration in tissue and cell lysates was adjusted to 0.3 mg/ml with CSB 1 
(Zeptosens) before spotting onto ZeptoMARK hydrophobic chips in a four-fold serial dilution 
in duplicate using a contact free NP2.1 spotter (GeSiM). The volume per spot was 
approximately 400 pl. Reference spots in four equally spaced columns across the array were 
spotted with Alexa647-labelled BSA. One chip contained six replicate arrays, each array 
could be probed with a different antibody. After spotting, the chips were blocked for one hour 
in the ZeptoFOG blocking station with blocking buffer BB1 (Zeptosens).  
2.4.2. Western blots 
In order to ensure antibody specificity western blotting on control samples was performed for 
all antibodies applied on ZeptoMARK reverse protein arrays. 30 µg of total protein were 
diluted in ddH2O to a final volume of 20 µl. 20 µl 4X sample buffer were added (Laemmli) and 
the samples were boiled at 95°C for 5 min. Samples were then loaded on handcast gels of 
appropriate acrylamide percentage (see Table 2) including a prestained protein marker 
(peqGold IV from PeqLab with a MW range from 10-170 kDa) and SDS-PAGE was run for 
45-50 min at 200 V. Proteins were blotted on nitrocellulose membranes at 1mA/cm2 using a 
semi-dry blotting unit from Hoefer Laboratories. The transfer buffer contained 20% methanol. 
Transfer efficiency and absence of air bubbles in the blotting sandwich was monitored by 
Ponceau S staining of the membrane. Membranes were then blocked using the blocking 
solution for nitrocellulose membranes from the WesternBreeze® Western blotting kit from 
Invitrogen for at least 1h at room temperature and incubated overnight at 4 °C in the same 
blocking solution with the primary antibody at an appropriate dilution (see Table 2). Washing 
of the membranes, incubation with the alkaline phosphatise-conjugated secondary antibody 
and chemiluminescence detection of bands was carried out according to Invitrogen’s 
WesternBreeze protocol for all mouse primary antibodies. Images were acquired with a CCD 
camera from Αlpha Innotech and the AlphaEaseFC software. Blots for the FKRP antibody 
were incubated with 1:2500 rabbit anti-goat horseradish peroxidise-conjugated secondary 
antibody (Chemicon) and the substrate for chemiluminescence detection was SuperSignal 
West Pico from Pierce. Images for FKRP blots were acquired using Kodak scientific imaging 
films on a Curix60 processor and films were scanned using a calibrated densitometer (model 
GS-800, Bio-Rad).  
Quantitation of Western blot bands was carried out using the QuantityOne (version 4.6.1) 
software package from Bio-Rad. Average band intensities were used in all calculations. 
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2.4.3. Reverse protein array assays 
Arrays were incubated overnight with the primary antibodies diluted in CAB1 or CAB2 assay 
buffer (Zeptosens). After two hours incubation with secondary fluorescence-labelled 
antibodies (Alexa Fluor® 633 goat anti-mouse IgG from Invitrogen) for IgG1 and 
fluorescence-labelled Fab fragments (Invitrogen) for IgG2a and IgG2b primary antibodies, 
fluorescence intensity was measured by using the red excitation/emission channel of the 
ZeptoReader detection system. In an introductory set of reverse protein array experiments, 
optimal assay conditions were evaluated for all antibodies (data not shown). Four different 
antibody dilutions, two assay buffers and fluorescence-labelled detection antibodies or Fab-
fragments, respectively, were tested. Optimal assay conditions for each antibody were then 
chosen according to dose-dependant signal linearity and minimal background fluorescence. 
The IgG1-type antibodies from Novocastra applied in this study yielded optimal results at a 
dilution of 1:10 while for all other antibodies a dilution between 1:250 and 1:5,000 (MHC 
slow) proved to be adequate (see Table 2). 
2.4.4. Image analysis 
Images were analyzed using ZeptoView Pro software with automatic spot finding and 
individual local background subtraction for each spot. The excitation light intensity at each 
spot position was calculated from the weighted linear least square fits to the reference spot 
signals of the same row. Referenced fluorescence intensity (RFI) values were calculated 
using an error weighted linear fit of the four serial dilutions of the samples on the chip. 
Signals from unspecific binding of secondary antibodies to the samples were subtracted for 
each sample individually. Serial dilution of the samples on the chip allowed confirmation that 
all assays were in the linear measurement range. 
2.5. Two-dimensional gel electrophoresis 
2.5.1. General 2DE  
100 µg of total protein in CLB1 were loaded on 17 cm pH 3-10 nonlinear IPG strips (Bio-Rad) 
in 300 µl rehydration buffer (7 M urea, 2 M thiourea, 60 mM DTT, 2% CHAPS, 0.5% carrier 
ampholytes with a trace of bromophenol blue). Strips were rehydrated at 50 V for at least 8 h 
and isoelectric focusing was carried out using the following conditions: 1-200 V in 1min 
(linear gradient), 1 h at 200 V, 200-500 V in 1 min (linear gradient), 1 h at 500 V, 500-1000 V 
in 30 min (linear gradient), 1000 V for 1.5 h, 1000-10000 V in 5 h (linear gradient) and 7 h at 
10000 V. After focusing the strips were equilibrated in 6 M Urea, 30% glycerol, 5% SDS and 
50 mM Tris-HCl pH 8.8 with 1% DTT and subsequently with 260 mM iodoacetamide. 
Equilibrated strips were either frozen at -20 °C un til further processing or placed directly on 
top of handcast 10% SDS-PAGE gels. Gels were run at 40 mA for 45 min and at 30 mA to a 
total of 1 kVh. 
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For 24 cm pH 3-10 nonlinear IPG strips 120 µg of total protein in CLB1 were loaded in 450 µl 
rehydration buffer and isoelectric focusing conditions were equal to those applied on 17 cm 
strips.  
 
Table 3: 2DE experiment list 
Number Genotypes Members 
EXP I (EXP159) 
DMD 
BMD 
Control 
 
DMD 5 
DMD 9 
DMD 15 
BMD 1 
BMD 2 
CONT 3 
CONT 4 
CONT 5 
CONT 6 
CONT 8 
CONT 9 
EXP II (EXP162) DMD Control 
DMD 3 
DMD 5 
DMD 6 
DMD 7 
DMD 15 
CONT 3 
CONT 4 
CONT 5 
CONT 6 
CONT 7 
EXP III (EXP 
161) 
LGMD2I 
Control 
LGMD2I 2 
LGMD2I 3 
LGMD2I 4/6* 
LGMD2I 7 
CONT 5 
CONT 6 
CONT 9 
Number Genotypes Members 
EXP IV (EXP 
167) 
LGMD2A 
LGMD2I 
Control 
LGMD2A 2 
LGMD2A 3 
LGMD2A 4 
LGMD2I 4 
LGMD2I 5 
LGMD2I 6 
CONT 1 (a) 
CONT 1 (b) 
CONT 2 (a) 
CONT 2 (b) 
EXP V (EXP 
168) 
DMD 
LGMD2A 
Control 
DMD 9 
DMD 12 
DMD 15 
LGMD2A 1 
LGMD2A 3 
LGMD2A 4 
CONT 1 (a) 
CONT 1 (b) 
CONT 2 (a) 
CONT 2 (b) 
* pooled   
   
   
   
   
   
   
   
 
2.5.2. Silver staining  
Silver staining was carried out according to Sinha et al. [88].  In brief, gels were fixed in two 
changes of 30% ethanol/10% acetic acid for 1 h and overnight, sensitized for 45 min in 3 g/L 
potassium tetrathionate, 0.5 M potassium acetate and 30% ethanol, rinsed 6 times 10 min in 
water and impregnated for 1 h with 2 g/L silver nitrate. After a brief rinse of the gels in water, 
development was carried out in 30 g/L potassium carbonate with 300 µl 37% formaldehyde 
and 125 µl 10% sodium thiosulfate pentahydrate per litre. Development was stopped in 40 
g/L Tris base with 5% acetic acid for at least 30 min. After rinsing the gels in water images 
were acquired using a densitometer.  
Gels were stored in closed boxes at 4 °C in 5% acet ic acid until spot excision and further 
processing.  
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2.5.3. Image analysis 
Gel images were acquired using a calibrated densitometer from Bio-Rad (model GS-800). 
Images were processed using QuantityOne and analyzed using the PDQuest software 
package from Bio-Rad (Version 8.0). Spots were detected using the advanced spot detection 
mode with the following parameters: Sensiitivity: 40; Spot size scale: 9; minimum peak: 130. 
In EXP I sensitivity was 69.7, size scale was 9, and minimum peak was 1451. Horizontal and 
vertical streaks in the images were removed and the automated speckle filter was applied. 
After spot finding, spots with a quality below 25 and/or intensity below 10 were cancelled and 
remaining misinterpreted spots such as air bubbles or gel edges were cancelled manually. 
Gels were then matched using automated matching and some landmark spots present in all 
gels in an experiment. In order to compensate for non expression-related differences in spot 
intensities, the LOESS model included in the PDQuest software was applied for 
normalization. The model corrects differences in labelling efficiency at different concentration 
levels in the gels. A curve in the scatter plot (experiment master gel vs. member gel) is 
calculated that minimizes the distance to all points in the plot and this curve is then used to 
calculate the normalization factor for each spot. Normalized qualitative and quantitative (OD 
normalized>4fold differences between groups) analysis sets were evaluated and carefully 
reviewed spot by spot in the spot review mode. Analysis sets were then created in the spot 
review mode and exported to Microsoft Excel spreadsheets.  
2.5.4. Isoelectric Fractionation (IEF) and narrow-range 2DE 
Total muscle protein extracts were separated on the basis of their isoelectric point (pI) into 
five fractions prior to application to narrow-range IPG strips using the ZOOM® solution phase 
IEF system (Invitrogen) in order to achieve higher resolving power in 2DE analyses. 
Muscle tissue was homogenized in CLB1 as described in the sample preparation in the 
microarrays section. Protein content was determined using the Bradford assay (Bio-Rad) and 
four control or patient samples respectively (480 µg from each individual control/patient) were 
pooled in order to have 1.95 mg total protein for isoelectric fractionation. To these pooled 
samples in CLB1, 32.5 µl ZOOM® focusing buffer pH 3-7 and pH 7-10 (Invitrogen) 
respectively, 16.25 µl 2M DTT, a trace of bromophenol blue as tracking dye and protein 
solubilizer (7 M Urea, 2 M Thiourea, 1% CHAPS) to 3.25 ml were added. This resulted in 650 
µl sample containing 0.6 mg/ml protein in each of the five sample chambers. The ZOOM® 
IEF system was assembled using pH disks 3.0, 4.6, 5.4, 6.2, 7.0, and 10.0. IEF was carried 
out for 20 min at 100 V, for 1 h 20 min at 200 V and for 2 h at 400 V. The resulting five 
fractions were then collected and remaining proteins adherent to the sample chamber walls 
were collected after washing the sample chambers with 293 µl IEF denaturant (7.7 M Urea, 
2.2 M Thiourea, 4.4% CHAPS, deonized overnight using mixed bed ion exchanger resin 
Amberlite NB-150 (Sigma), and filtered trough a 0.2 µm PVDF filter) and 3 µl 2 M DTT on a 
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shaker for 10min. These solutions were stored separately. Protein concentrations in the 
fractions were determined using the Bradford assay in order to adjust protein concentrations 
between control and DMD samples rather than to have an absolute protein concentration. 
2.5.5. Protein identification of selected spots from 2D Gels  
Spots of interest were cut manually using a sterile syringe or razor blade and washed three 
times in 50 mM ammonium bicarbonate (pH 8.5)/50% acetonitrile for 30 minutes each. Spots 
were incubated with 200 µl 0.2 M TCEP in 50mM ammonium bicarbonate at 37 °C for 1 h 
and subsequently with 200 µl with 10 mg/ml iodocacetamide in 50 mM ammonium 
bicarbonate at 25 °C for 1 h in the dark. Gel piece s were washed in 50 mM ammonium 
bicarbonate/50% acetonitrile, overlaid with acetonitrile and dried under vacuum. 200 µl 10 
µg/ml sequencing grade porcine trypsin (Promega) were added and left overnight at 37 °C. 
Peptides were extracted sequentially in 50% acetonitrile/0.1% TFA, 60% acetonitrile/0.1% 
TFA, and 80% acetonitrile/0.1% TFA in a waterbath with sonication for 10 min each and were 
pooled with the supernatant from the trypsinisation step. The extracts were dried under 
vacuum, reconstituted in 10 µl 0.1% TFA, and desalted using C18 peptide cleanup tips 
(Agilent). Eluates containing peptides were dried under vacuum and then reconstituted in 10 
µl 5% acetonitrile/0.1% formic acid. 
HPLC-ESI MS/MS analysis of tryptic peptides was performed using an Agilent Ion Trap XCT 
Plus mass spectrometer (MS) connected to an Agilent Model 1100 Nanoflow HPLC system 
with an Onyx monolithic C18 capillary column (Phenomenex) and an acetonitrile/0.1% formic 
acid in H2O gradient. Capillary voltage was 3500 V and mass spectra were obtained in the 
positive ion reflector mode. MS/MS acquisitions were performed on precursors over a mass 
range of 200-2200 Da. Single-charged precursors were excluded and spectra were actively 
excluded from auto-MS/MS after two spectra for 30 sec.  
Protein identification was performed by database searches correlating the tandem mass 
spectra to entries in the SwissProt database (Homo sapiens) using Spectrum Mill protein 
identification software (Agilent). Three missed cleavages per peptide were allowed and 
carbamidomethylation of cysteines was assumed. A distinct summed MS/MS search score 
>12 in Spectrum Mill was considered sufficient for protein identification as suggested by the 
software manual. Individual selected spots were additionally analyzed at the mass 
spectrometry facility at the Biozentrum in Basel. Their equipment was a Finnigan LTQ-
Orbitrap Mass Spectrometer and the protein identification software was MASCOT. 
2.6. Immunofluorescence 
C2C12 cells and primary human muscle cells were grown and differentiated (as described 
before) on 12 mm glass coverslips that have been sterilized by dipping in ethanol and 
flaming in a sterile bench. Coverslips were washed in PBS before the cells were fixed in 4% 
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paraformaldehyde for 10 min at room temperature. Coverslips were washed twice in PBS 
and cells were then permeabilized for 10 minutes in 0.2% Triton X-100. Coverslips were 
rinsed in four changes of PBS prior to blocking in 5% of either horse or goat serum 
depending on the host species of the primary antibodies.  
Mouse and rabbit primary antibodies were diluted in 5% goat serum while goat primary 
antibodies were diluted in 5% horse serum and coverslips were incubated sample side down 
on 25 µl of antibody solution on Parafilm at 4°C in the da rk overnight. After three washes in 
PBS coverslips were incubated sample side down on 25 µl of secondary antibody solution 
(Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488 chicken anti-goat, actin-phalloidin all 
diluted 1:1000 in the appropriate 5% serum). After additional three washes in PBS coverslips 
were either rinsed twice in Nanopur H2O before mounting or incubated sample side down in 
DAPI (diluted 1:1000 in PBS), then rinsed three times in PBS and twice in Nanopur H2O. 
Coverslips were mounted on microscopy slides in Mowiol with 2.5% DABCO and allowed to 
set overnight at 4 °C in the dark before image acqu isition. Images were acquired with a Zeiss 
Axiovert 40 CFL inverted microscope and the AxioVision software package.  
For immunofluorescence experiments, primary antibodies were diluted as follows: desmin 
1:100, HSPβ2 1:25, VDAC2 1:25.  
2.7. Statistical analyses 
Statistical analyses were carried out and all bar- and boxplots were created using the R 
software environment [89]. Welch two-sided t-tests (p=0.05) were performed to compare 
mean signal intensities in reverse protein arrays. 
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3. RESULTS 
 
3.1. Reverse protein arrays for quantitation of protein patterns in mucular 
dystrophies 
3.1.1. Validation of antibody specificity 
Western blot analysis was performed on healthy human muscle lysates to give further 
evidence for the specificity of the antibodies applied on the reverse protein arrays, because 
unspecific binding to other proteins in the lysates cannot be identified on the array and might 
therefore lead to false-positive results. Strong single or double (calpain-3, DYS1, and DYS2 
as stated by the manufacturer) bands were seen for 14 out of 25 tested antibodies (see 
Figure 5). Band sizes in Figure 5 are calculated relative to the molecular weight marker (10-
170 kDa) and band sizes larger than 170 kDa are therefore estimations. Some bands 
appeared slightly higher or lower than expected, which can be caused by glycosylation of the 
protein that causes altered migration in SDS-PAGE. The anti-merosin antibody produced 3 
bands on commercially available purified human merosin, but not on the muscle lysates. α-
actinin, GPD1L, VDAC2 (a), as well as the MHC slow antibodies yielded multiple bands. The 
dysferlin antibody (mouse monoclonal) was tested on mouse muscle lysates and therefore 
produced two bands corresponding to mouse IgGs. α-dystroglycan, NCL-DYS3, HSPβ2, 
spectrin and utrophin antibodies did not show clear bands on the Western blots. 
 
 
 
Figure 5: Western blots of antibodies applied on reverse arrays (except for VDAC2 (b) that was not 
included in the reverse protein array study). A: α-actinin; B: α-sarcoglycan; C: β-dystroglycan; D: β-
sarcoglycan; E: β-tubulin; F: calpain-3; G: δ-sarcoglycan; H: desmin; I: dysferlin; J: dystrophin (NCL-
DYS1); K: dystrophin (NCL-DYS2); L: emerin; M: FKRP; N: γ-sarcoglycan; O: GPD1L; P: merosin; Q: 
MHC fast; R: MHC slow; S: VDAC2 (a); T: VDAC2 (b). All western blots were carried out on healthy 
human muscle except for dysferlin (I, carried out on mouse muscle), and merosin (P, carried out on 
purified human merosin protein). Band sizes do not exactly match the protein sizes indicated in Table 
2, because they are measured on the membrane relative to the protein MW marker. Band sizes that 
are larger than 170 kDa are estimations.  
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3.1.2. Muscle tissue lysate arrays 
Assays on muscle tissue were carried out for all 19 antibodies that were evaluated in the 
preliminary antibody tests. An example array layout is given in Figure 6.  
As shown in Figure 7 (left panel) and in Figure 6, the DYS1 antibody yielded particularly 
significant results. DMD samples showed almost no signal after background subtraction 
whereas the control samples showed distinct high fluorescence signals. BMD samples 
showed an intermediate mean signal indicating that these patients express lower levels of 
dystrophin compared to healthy controls. However, the range of residual dystrophin in BMD 
patients was highly variable and as only three BMD samples were analyzed, the difference 
between DMD and BMD samples was not significant in this study. DMD and BMD patients 
showed significantly lower DYS1 levels than LGMD patients even though DYS1 levels 
appeared to be slightly reduced in LGMD2A patients. The DYS2 antibody could only 
differentiate DMD patients from controls or LGMD2A patients who showed higher DYS2 
signals (Figure 7; middle panel). BMD samples did not significantly differ from controls. For 
both DMD and BMD samples the difference to LGMD2A patients was significant but not 
those to LGMD2D. 
A similar but less pronounced pattern than for DYS1 was observed for the DYS3 antibody 
(Figure 7; right panel). Although the overall signal intensities (RFI values) were much lower 
and the DMD samples still showed some fluorescence signals they could be clearly 
distinguished from the control samples. DYS3 signals BMD samples were again (as for 
DYS2) not significantly lower compared to controls. For DMD samples the mean difference to 
LGMD2A and LGMD2D was significant, which was not true for BMD samples. 
 
Figure 6: Left panel: Array layout, all samples were spotted in duplicate in a fourfold dilution series. 
Right panels: Arrays probed with DYS1, calpain-3, and VDAC2 (from left). 
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Figure 7: Boxplots for dystrophin signals on reverse protein arrays. Blue boxes represent significant 
mean differences from control group (t-test, two sided, p<0.05). Sample sizes were n=9 for controls 
and DMD patients, n=3 for BMD patients and n=4 for LGMD2A and LGMD2D patients.  
   
 
 
Figure 8: Boxplots for dystroglycan, α-, β-, γ-, and δ-sarcoglycan RFI signals on reverse protein 
arrays. Blue boxes represent mean RFI values that differ significantly from the control group (t-test, 
two sided, p<0.05).  Sample sizes were n=9 for controls and DMD patients, n=3 for BMD patients and 
n=4 for LGMD2A and LGMD2D patients. 
 
Secondary reductions in dystroglycans and sarcoglycans in DMD/BMD patients could be 
monitored on the reverse protein arrays (see Figure 8). DMD patients showed significant 
reductions in both dystroglycans, α-, and γ-sarcoglycan. Significant α- and γ-sarcoglycan 
reductions could be detected as well in BMD patients. Overall, secondary reductions in 
sarcoglycans in DMD patients resulted in 77%, 83%, 71%, and 89% remaining protein 
compared to controls in this study for α-, β-, γ- and δ-sarcoglycan, respectively.  
LGMD2D patients showed significantly lower α-sarcoglycan RFI values than controls as well 
as (secondary) reductions in α-dystroglycan, β-, and γ-sarcoglycan. In order to distinguish 
between secondary reductions in DMD patients and LGMD2D patients only β- and γ-
sarcoglycan can be applied as they show a significant difference between mean RFI values. 
The measurement of α-sarcoglycan on the reverse protein arrays is not sufficient to  
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Figure 9: Boxplots for calpain-3, spectrin and desmin RFI signals on reverse protein arrays. Blue 
boxes represent mean RFI values that differ significantly from the control group (t-test, two sided, 
p<0.05).  Sample sizes were n=9 for controls and DMD patients, n=3 for BMD patients and n=4 for 
LGMD2A and LGMD2D patients. 
 
discriminate between the primary (in LGMD2D) and secondary (in DMD/BMD) reductions. 
In LGMD2A patients all sarcoglycans showed slightly higher RFI values than controls and 
other groups, for β- and δ-sarcoglycan this difference was significant. 
 Calpain-3 levels could also be measured on reverse protein arrays (see Figure 9, left 
panel) but RFI values between LGMD2A patients and controls (as well as LGMD2D patients) 
did not allow a separation of LGMD2A patients from controls and other dystrophies. 
Interestingly, DMD and BMD samples had higher RFI values for calpain-3 compared to 
LGMD2A/2D and controls (significant for DMD, but not for BMD). The outliers in the DMD 
groups seen for calpain-3 and for desmin levels do not come from the same samples giving 
further evidence that extreme high or low signals do not represent artefacts of total protein 
differences in samples. Spectrin levels were significantly higher in DMD patients than in 
controls (Figure 9, middle panel), and no significant differences for desmin could be 
demonstrated on reverse protein arrays even though a general tendendy of higher desmin 
levels in muscular dystrophies was seen (Figure 9, right panel). Out of the other tested 
antibodies (dysferlin, emerin, merosin, utrophin) no significant differences between groups 
were found (see Figure 10). Utrophin upregulation in DMD patients was not observed on 
reverse protein arrays even though the mean utrophin level in DMD patients was slightly 
higher than in controls. MHC slow and MHC fast did not show any significant differences 
(see Figure 11), and α-actinin II levels were only slightly higher in LGMD2D patients than in 
DMD patients.  
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Figure 10: Boxplots for dysferlin, emerin, merosin and utrophin RFI signals on reverse protein arrays. 
No significant differences were observed any patient group compared to controls. Sample sizes were 
n=9 for controls and DMD patients, n=3 for BMD patients and n=4 for LGMD2A and LGMD2D 
patients. 
 
 
 
Figure 11: Boxplots for MHC and α-actinin II RFI signals on reverse protein arrays. No significant 
differences were found between any patient group compared to control groups. Sample sizes were 
n=9 for controls and DMD patients, n=3 for BMD patients and n=4 for LGMD2A and LGMD2D 
patients. 
 
A protein that is probably the voltage-dependent anion channel (VDAC) 2 was found to be 
reduced in DMD and BMD patients in 2DE experiments. Using a mouse monoclonal antibody 
against this protein on reverse protein arrays a significant difference between DMD and BMD 
patients and controls could indeed be demonstrated, however, this antibody yielded multiple 
bands in Western blots and only a very weak band at the predicted MW for VDAC2 (see 
Figure 12, upper right panel). Therefore, a goat polyclonal antibody was evaluated that 
appeared more specific in Western blots, and the pattern that was obtained using the mouse 
monoclonal antibody could not be confirmed (see Figure 12, lower right and upper left panel). 
Even though the levels in DMD patients seemed slightly lower also when using the goat 
polyclonal antibody, a significant difference was not seen. In a Western blot including four 
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DMD and control samples, higher VDAC2 levels could not be seen using this antibody and, 
moreover, the band intensities from Western blot analyses did not correspond to the RFI 
signals from the reverse protein array using the same antibody and samples (see Figure 12, 
lower left panel) 
 
Figure 12: VDAC2 on reverse protein arrays and in Western blots. A: VDAC2a (mouse monoclonal) 
antibody yields multiple band in a Western blot with a very weak band at the predicted protein size. 
DMD patients show significantly lower RFI values using this antibody. B: Lower RFI values can no 
longer be seen using VDAC2b (goat polyclonal) antibody showing only one band at the predicted MW. 
C: RFI signals for VDACa and VDACb do not show a strong correlation. D: Band intensities on 
Western blot for VDAC2b and corresponding RFI signals do not correspond to a large extent.  
 
3.1.3. Correlation with Western blot data 
Data from muscle tissue lysate arrays showed a strong correlation with the Western blot 
analyses performed on the same samples (see two examples in Figure 13). In general, 
strong bands in Western blots corresponded to high RFI values on the reverse protein arrays 
and faint bands corresponded to low RFI values.  
For example, the values for dystrophin of patient DMD6 using DYS1 were between those of 
the DMD and BMD samples, which is consistent with the clinical presentation of patient who 
as an intermediate DMD/BMD phenotype (data not shown) and is seen as the outlier in the 
DMD group of the DYS1 boxplot in Figure 2. 
Calpain-3 expression levels could be monitored using reverse protein arrays, the RFI 
values correlated mostly with Western blot data where patient LGMD2A 2 showed 
normal calpain-3 bands (see Figure 15). CONT2 showed an intermediate RFI signal, 
CONT 16 that appeared normal on the western blot was however indistinguishable from 
patients LGMD2A 3 and 4. Samples with unknown genotype (suspected LGMD2A) had 
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particularly high calpain-3 levels both on Western blots and on reverse protein arrays. In 
DMD samples, calpain-3 levels wfere found to be very variable on microarrays (see Figure 9) 
but also on Western blots (see Figure 15).  
 
 
Figure 13: Correlation of Western blot data with microarray signals. Left panels: Average band 
intensities in Western blots are dark grey, respective microarray signals of the same samples are light 
grey. WB: Western blot; MA: Microarray. Right panels: Western blot sections with corresponding 
microarray sections. Sample DMD 9 was not analyzed on Western blot because no sample was left.  
 
 
 
Figure 14: Comparison of Western blot and reverse array data for desmin. Overall good correlation 
with some exceptions such as LGMD2A 1. WB: Western blot; MA: microarray. 
 
 
 
Figure 15: Calpain-3 signals on reverse protein arrays (upper panel, A and C) and corresponding 
bands in Western blots (on independent gels, lower panel, B and D). Patient LGMD2A 2 shows 
persistent calpain-3 expression on reverse arrays as well as in Western blot. DMD patients show 
higher calpain-3 expression than controls in some cases.  
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3.1.4. Microarrays from cultured primary human muscle cells 
Assays for lysates of cultured primary muscle cells were carried out using 13 antibodies. 
DMD cells showed generally lower RFI signals using the antibodies against proteins of the 
DGC complex than control cells. Due to very small sample sizes (n=3 for controls and 
LGMD2D, n=2 for DMD, BMD and carriers), most of those differences reached no statistical 
significance. As in the muscle tissue samples the signals obtained with the DYS1 antibody 
were significantly lower in cell lysates from DMD patients compared to those from BMD 
patients and both DMD and BMD cells had a significantly reduced dystrophin expression 
compared to control cells (in DMD 1%, in BMD 9%; see Figure 6; left panel). The difference 
between the DMD and the BMD samples using the DYS2 antibody was more pronounced 
than in tissue lysates. Cells from the LGMD2C patient showed a very similar protein 
expression pattern to the cells from LGMD2D patients. The RFI value for α-sarcoglycan was 
slightly higher in cells from LGMD2C than in LGMD2D. A stronger reduction of γ-sarcoglycan 
in the cells from the LGMD2C patient compared to LGMD2D cells could not be observed 
(data not shown). Female DMD Carriers showed an intermediate signal between controls 
and DMD/BMD cells for dystrophin using all three dystrophin antibodies (see Figure 16), but 
no significant differences between the control group and the female DMD carriers could be 
observed. Sarcoglycans and dystroglycans, on the other hand, did not seem to be reduced in 
the female DMD carriers (see Figure 17). Desmin levels that could be regarded as an 
indicator of myogenicity in the muscle cell cultures varied considerably between and within 
the sample groups (data not shown). 
 
 
Figure 16: Boxplots for dystrophin signals in myotubes on reverse protein arrays. Sample sizes were 
n=3 for controls and n=2 for all patient groups.  
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Figure 17: Boxplots for the dystroglycan and sarcoglycan signals in myotubes on reverse protein 
arrays. Sample sizes were n=3 for controls and n=2 for all patient groups 
 
 
3.1.5. Reproducibility of microarray results 
A reproducible sample preparation is crucial for reliable assay performance. Reproducibility 
of the sample preparation was assessed in a first series of microarray assays by multiple 
sample preparation and calculation of coefficients of variation (CV) for each sample and 
antibody. The average CV of 18.3% shows a good overall assay reproducibility including 
sample preparation even without normalization. Out of 72 samples with respective 
antibodies, 46 had a CV below 20%, 18 were between 20% and 30% and only 8 were above 
30% (see Table 4).  
 
Table 4: CV overview for selected samples prepared repeatedly (n=2 for DMD10, CONT 10, and 
CONT 1; n=3 for DMD 9, BMD 1, and CONT2) for reverse protein arrays 
Sample α-SG α-DG β-SG β-DG δ-SG DYS1 
DMD 9 9.5% 16.9% 7.6% 13.3% 12.1% 7.0% 
DMD 10 10.2% 17.9% 18.1% 19.3% 38.9% 30.4% 
BMD 1 12.4% 9.3% 19.8% 18.3% 23.9% 16.0% 
CONT 2 16.9% 15.4% 20.1% 19.7% 17.1% 24.3% 
CONT 10 33.3% 27.3% 34.6% 34.7% 21.5% 25.1% 
CONT 1 19.2% 12.6% 14.1% 17.1% 0.8% 23.6% 
       
Sample DYS2 emerin γ-SG merosin myosin utrophin 
DMD 9 19.2% 7.9% 13.3% 30.7% 28.7% 18.7% 
DMD 10 25.6% 12.5% 20.7% 9.3% 15.1% 24.6% 
BMD 1 14.5% 8.2% 4.4% 20.0% 25.9% 1.5% 
CONT 2 22.8% 4.0% 11.8% 26.5% 23.1% 29.4% 
CONT 10 30.3% 28.3% 4.1% 46.9% 14.9% 7.5% 
CONT 1 11.4% 16.2% 19.1% 20.9% 5.6% 6.3% 
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Similar to Western blotting, reverse protein arrays provide relative information of measures. 
The name “RFI” indicates that results are quantified according to the fluorescence intensity of 
the control spots consisting of Cy5-labelled BSA on the array. Therefore, RFI values from 
different experiments cannot be compared in absolute values. In two independent runs four 
identical samples were spotted on reverse protein arrays and RFIs were compared. R2 as an 
indication of linear regression was 0.93 on average for DYS1, DYS2, the dystroglycans as 
well as α-, β-, γ-, and δ-sarcoglycan respectively (see Figure 18). Best correlations were 
seen for DYS2 and γ-sarcoglycan (both 0.99), and α-dystroglycan showed the lowest R2 of 
0.56. Possible sources of variation in replicates on reverse protein arrays from different 
experiment runs include (possibly among others): sample preparation, determination of total 
protein concentration, spotting, antibody concentrations/performance, laser intensity, and 
array quality. In order to assess the reproducibility of the overall method twelve biopsies were 
divided in two pieces and assessed independently in two different experiment runs (see 
Figure 19). The average R2 was 0.71 and therefore markedly lower compared to the 
comparisons between two experiment runs and identical samples. RFI values for DYS1 and 
DYS2 showed both a high correlation of 0.92 between run 3 and run 4. Again, α-dystroglycan 
showed the lowest R2-value of in this case only 0.21. 
 
 
Figure 18: Linear regression for reproducibility of results between runs (run 1 vs. run 2, n=4). Identical 
sample preparations were spotted twice on reverse protein arrays. R2 as an indication of linear 
regression was 0.93 on average with the lowest value for a-dystroglycan (R2=0.56).  
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Figure 19: Linear regression for reproducibility of results between runs (run 3 vs. run 4, n=12). 
Sample preparation and determination of total protein concentration for spotting was completely 
independent in both runs. R2 as an indication of linear regression was 0.71 on average with the lowest 
value for a-dystroglycan (R2=0.21). 
 
 
3.1.6. Normalization to muscle “housekeeping” proteins 
In a preliminary study normalization of RFI signals to α-actinin led to a slight decrease of the 
overall CV in all sample groups. Therefore, it was assumed that normalization of the signals 
to muscle “housekeeping” proteins could compensate for the various amounts of actual 
muscle tissue in the biopsies. 
Average CVs in sample groups of the microarray containing nine control, nine DMD, three 
BMD, and each four LGMD2A and LGMD2D samples were 23% without normalization for all 
antibodies except candidate normalizing proteins. Here, normalization to α-actinin and β-
tubulin (in CAB1) increased the average CV to 30% and 34% respectively. Normalization to 
myosin fast heavy chain, myosin slow heavy chain, β-tubulin in CAB2 led to dramatic 
increases of CVs (>50%) over all sample groups indicating that normalization of signals to 
these proteins is not feasible on reverse protein arrays.  
Normalization to α-actinin and β-tubulin did not have an impact on statistical decisions in 
most cases indicating good assay stability. DMD patients showed still significantly lower 
DYS1 and DYS3 signals after normalization, only with DYS2 this was not the case (see 
Figure 20). α-sarcoglycan levels in LGMD2D were significantly lower compared to control 
samples after normalization to α-actinin or β-tubulin. For the other sarcoglycans and 
dystroglycans as well as calpain and spectrin, statistical decisions remained mainly 
unchanged however some sample groups differed no longer after normalization. The only 
case where a sample group differed significantly from the control group only after 
normalization was the increased signal for α-sarcoglycan in LGMD2A patients. Desmin 
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normalization increased markedly the overall CVs in the tissue as well as in the myotube 
arrays.  
If muscle proteins in myotubes should be assessed, myogenicity of the myoblast cultures has 
to be carefully monitored. As seen in Western blots of total cell lysates from developing 
myotubes (in Figure 21), the contents of α-actinin and desmin as muscle-specific proteins 
vary dramatically between cultures. While sample CONT 14 shows the typical increase of α-
actinin over differentiation time and the developmental pattern of desmin expression, in 
CONT 15 α-actinin levels increase slower and desmin expression is seen only at very low 
level. The same was found in immunofluorescence analysis (see Figure 22), where in the 
culture of CONT 15 at day 0 indeed only single desmin-positive cells were found and after 5 
days of differentiation myotube formation was negligible.  
 
 
Figure 20: Normalization of RFI signals to candidate „housekeeping“ proteins. For DYS1 and DYS3, 
normalization to α-actinin levels or β-tubulin levels do not have an impact on statistical decisions. In 
contrast, DYS2 signals in DMD patients do not differ significantly from controls after normalization. 
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Figure 21: Desmin and α-actinin in differentiating control myoblasts from primary culture. Myogenicity 
can vary dramatically between cultures as seen in the amounts of desmin and α-actinin. CONT 15 
shows considerably lower desmin levels compared to CONT 14. Right panel: Densitometric analysis of 
bands on western blots (average intensity).  
 
 
Figure 22: Desmin in myoblasts and myotubes in two control muscle cell cultures. Green cells are 
desmin-positive, red is actin-phalloidin and blue is DAPI staining. CONT 14 shows considerably more 
desmin-positive cells (higher myogenicity) on day 0 than CONT 15 where only single desmin-positive 
cells are seen. On day 5 of differentiation, multinucleated myotubes are formed in CONT 14 culture 
while in CONT 15 only one myotube-like cell was found in the culture. 
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3.2. Two-dimensional gel electrophoresis 
 
Figure 23 shows representative 2DE gels for DMD and control muscle tissue obtained with 
either 17cm nonlinear IPG strips for isoelectric focusing (left panels) or 24cm nonlinear IPG 
strips (right panels). After manually cancelling misinterpreted spots the average number of 
spots found on large gels was slightly higher than on smaller gels but the most striking 
advantage of the larger gels is the considerably higher resolution in extreme pH ranges. 
Average number of spots found in the experiments was lowest in EXPV (504 spots) and 
highest in EXPIII (869) and probably depended on the moment of the stopping of the silver 
staining. 
 
Figure 23: Total muscle tissue protein extracts from control and DMD muscle on 17cm nonlinear IEF 
strips/10% acrylamide gel (left, 90µg total protein, from EXPI) and 24cm nonlinear IEF 
strips/10%acrylamide gel (right, 120µg total protein, from EXP II); silver stained. Higher resolution 
especially in extreme pH range is reached on 24cm strips.  
 
3.2.1. HPLC-MS/MS analysis of selected spots 
Landmark spots were identified by HPLC-MS/MS in order to compare the gels from human 
muscle tissue with gels from databases or literature. 61 spots were analyzed and the 
corresponding proteins identified. Out of 47 proteins that were identified ten were found in 
more than one spot indicating that isoforms of the corresponding proteins are present in 
skeletal muscle. An example gel showing all the identified proteins is shown in Figure 24 and 
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the list of corresponding proteins is given in Table 5. The complete list of all peptides found in 
the HPLC-MS/MS analysis is given in Appendix I. Eight proteins (β-enolase (spot No. 3), 
HSP-β1 (No.5), L-lactate dehydrogenase A chain (No. 9), triosephosphate isomerase (No. 
11), myosin regulatory light chain 2 (ventricular/cardiac muscle isoform, No. 14), fructose-
bisphosphate aldolase A (No. 20), α-1 antitrypsin (No. 22), and peroxiredoxin-2 (No. 47) 
were identified in two spots while troponin C from slow skeletal muscle (spot No. 35-35c) and 
troponin C from fast skeletal muscle (spot No. 39-39c) were found in four different spots on 
the gel, some of them identified with only one peptide, though. Muscle proteins with a MW 
range from 83.3 kDa (HSP-90β) to 17.2 (myoglobin) and a pI range from 4.04 (Troponin C, 
slow skeletal and cardiac muscles) to 9.31 (zinc finger protein 705F) were identified on the 
gel. Zinc finger protein 705F (No. 42) was identified by only one peptide as well, but the 
position at the very basic edge of the gel indicates a high probability that spot No. 42 might 
indeed represent this protein with a MW of 34.9 kDa and a pI of 9.31. The general spot 
pattern on the gel based on MW/pI of the identified proteins (see Figure 24) was plausible 
with some exceptions such as spots No. 22, 24, 26, 29, 39, and 44 that appeared at 
positions on the gel not fully compliant with the spots in their close environment. Spot 16, in 
addition to tubulin β-2 chain (spot No. 16, UniProt No. P68371) was identified as tubulin β-3 
chain (UniProt No. Q13509) and twice as tubulin-β chain (P07437).  
 
 
Figure 24: All proteins identified after 2DE and HPLC-MS/MS on their position on a representative gel 
from human muscle tissue. The sample shown is LGMD2I 3.  
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Figure 25: Control muscle (pooled) on narrow-range-pI IEF/2DE (after ZOOM prefractionation). 
Numbers on top are pI ranges, numbers on gels are identified proteins from ZOOM gels. Overall 
resolution was not enhanced due to introduction of artefacts such as horizontal streaking.  
 
 
 
Table 5: List of identified proteins in human skeletal muscle tissue on 2DE gels 
Nr Unique Peptides 
Percent 
Coverage 
MW 
[kDa] pI 
Uniprot 
Nr Name Remarks 
1 12 48 29.6 6.86 P07451 Carbonic anhydrase 3 ******* 
2 11 30 43.1 6.77 P06732 Creatine kinase M-type ****, ****** 
3 12 32 47.0 7.58 P13929 Β-enolase *** 
3a 2 5 47.0 7.58 P13929 Β-enolase  
4 32 54 69.4 5.92 P02768 Serum Albumin  
5 3 20 22.8 5.98 P04792 Heat shock protein β-1  
5a 5 34 22.8 5.98 P04792 Heat shock protein β-1 ****, ****** 
6 11 72 19.0 4.91 Q96A32 Myosin regulatory light chain 2, skeletal muscle isoform *** 
7 9 48 21.9 5.03 P08590 Myosin light chain 3  
8 4 16 36.4 6.91 P40925 Malate dehydrogenase, cytoplasmic *** 
9 5 15 36.7 8.44 P00338 L-lactate dehydrogenase A chain **** 
9a 6 17 36.7 8.44 P00338 L-lactate dehydrogenase A chain  
10 4 32 20.2 6.76 P02511 Α-crystallin β chain  
11 6 32 26.7 6.45 P60174 Triosephosphate isomerase  
11a 2 12 26.7 6.45 P60174 Triosephosphate isomerase  
12 1 6 18.1 4.06 P02585 Troponin C, skeletal muscle  
13 2 13 18.4 4.04 P63316 Troponin C, slow skeletal and cardiac muscles  
14 4 21 18.8 4.92 P10916 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform *** 
14a 3 15 18.8 4.92 P10916 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform  
15 12 30 56.6 5.26 P06576 ATP synthase subunit β, mitochondrial ***, ****** 
16 3 8 49.8 4.79 P68371 Tubulin β-2 chain *** 
17 5 35 21.1 7.01 P30086 Phosphatidylethanolamine-binding protein 1 **** 
18 6 19 32.9 4.66 P07951 Tropomyosin β chain  
19 4 15 32.7 4.69 P09493 Tropomyosin α-1 chain  
20 8 26 39.4 8.3 P04075 Fructose-bisphosphate aldolase A **** 
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Table 5, continued 
Nr Unique Peptides 
Percent 
Coverage 
MW 
[kDa] pI 
Uniprot 
Nr Name Remarks 
20a 3 10 39.4 8.3 P04075 Fructose-bisphosphate aldolase A  
21 2 8 25.0 6 P30041 Peroxiredoxin-6  
22 3 6 46.7 5.4 P01009 Α-1 antitrypsin ****** 
22a 5 12 46.7 5.4 P01010 Α-1 antitrypsin ****** 
23 15 nd 38.4 6.61 Q8N335 Glycerol-3-phosphate dehydrogenase 1-like protein ***** 
24 3 nd 30.4 7.5 P45880 VDAC2  ***** 
 3 nd 36.4 6.91 P40925 Malate dehydrogenase, cytoplasmic ***** 
 2 nd 36.1 8.57 P04406 Glyeraldehyde-3-phosphate dehydrogenase ***** 
25 2 4 47.2 7.01 P06733 Α-enolase ** 
26 2 15 16.0 6.74 P68871 Hemoglobin subunit β  
27 7 13 57.9 7.95 P14618 Pyruvate kinase isozymes M1/M2  
 
 4 8 59.8 9.16 P25705 ATP synthase subunit α, mitochondrial  
29 19 46 42.1 5.23 P68133 Actin, α skeletal muscle ******* 
30 3 8 52.7 6.05 Q6ZMU5 Tripartite motif-containing protein 72  
31 2 8 30.8 5.56 P02647 Apolipoprotein A-I *** 
32 10 39 35.5 8.92 P40926 Malate dehydrogenase, mitochondrial  
33 1 3 35.9 4.94 P08758 Annexin A5  *** 
34 5 22 36.1 8.57 P04406 Glyceraldehyde-3-phosphate dehydrogenase  
35 2 7 32.9 5.86 P13805 Troponin T, slow skeletal muscle  
35a 4 10 32.9 5.86 P13805 Troponin T, slow skeletal muscle  
 2 7 36.6 5.71 P07195 L-lactate dehydrogenase B chain  
35b 1 3 32.9 5.86 P13805 Troponin T, slow skeletal muscle  
35c 2 7 32.9 6.86 P13806 Troponin T, slow skeletal muscle ****** 
36 11 19 77.1 6.81 P02787 Serotransferrin  
37 2 3 83.3 4.97 P08238 Heat shock protein HSP 90-β *** 
38 2 14 17.1 5.95 O14558 Heat shock protein β-6  
39 2 10 31.8 5.71 P45378 Troponin T, fast skeletal muscle  
39a 5 17 31.8 5.71 P45378 Troponin T, fast skeletal muscle  
39b 3 16 31.8 5.71 P45378 Troponin T, fast skeletal muscle  
39c 1 2 31.8 5.71 P45378 Troponin T, fast skeletal muscle  
40 8 57 17.2 7.14 P02144 Myoglobin  
41 4 14 37.6 5.81 P21695 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic  
42 1 7 34.9 9.31 A8MVS1 Zinc finger protein 705F  
43 19 41 53.5 5.21 P17661 Desmin *******  
44 3 7 55.9 8.54 P02675 Fibrinogen β chain **** 
45 3 10 28.9 6.59 P00915 Carbonic anhydrase 1  
48 1 8 20.2 5.07 Q16082 Heat shock protein β-2 **, *** 
47 2 10 21.9 5.66 P32119 Peroxiredoxin-2  
47a 2 10 21.9 5.66 P32119 Peroxiredoxin-2 **** 
* different parent charges; ** confirmed by experiments at the Biozentrum, Basel (Suzette Moes); *** confirmed by an additional 
experiment (at least one more unique peptide; **** confirmed by an additional experiment (at least one unique peptide), ***** 
identified the Biozentrum, Basel (Suzette Moes); ****** data from ZOOM experiment; ******* confirmed in ZOOM experiment 
 
 58 
In order to enhance resolution in the first dimension of 2D-PAGE a prefractionation of the 
sample was carried out using Invitrogen’s ZOOM system for fractionation of protein samples 
according to pI in solution. Sample fractions were then applied to narrow-range matching IEF 
strips resulting in three gels per sample with an overlapping pH range. Running all three gels 
in the same gel run resulted in comparable separation according to MW over all three tells. 
As shown in Figure 25, this additional sample step introduced considerable experimental 
artefacts such as horizontal streaking and a smaller number of total protein spots rather than 
higher resolution. As a consequence, comparisons between muscle tissue lysates from 
patients and controls were all carried out on single pH 3-10 nonlinear IEF strips in the first 
dimension.  
3.2.2. Differentially expressed proteins between in DMD muscle tissue 
Eight spots were reproducibly found to be differentially expressed between DMD muscle 
tissue and healthy control tissue in the present sample set in EXP I and EXP II. HSP β-2 
(HSPβ2), α-enolase, annexin-A5 as well as two unknown proteins were found to be 
increased in DMD muscle tissue compared to controls while a protein that was identified as 
VDAC2 at the Biozentrum, GPD1L, and an isoform of troponin T fast skeletal muscle isoform 
were found to be decreased in patient tissue. The most prominent increases were those of 
HSPβ2 (not detectable in controls in EXP I and 8.51-fold increased in EXP II) and unknown 
protein II (not detectable in controls in EXP I and 8.46-fold increased in EXP II). VDAC2 
(likely) and GPD1L were decreased dramatically with VDAC2 being non-detectable in 
controls in both experiments and GPD1L detected only in EXP II. An overview on fold-
changes and p-values between DMD patient samples and controls is given in Table 6 and 
images of the spots representing the differentially expressed proteins are shown in Figure 
26. In EXP I the two BMD samples showed intermediate mean values between DMD and 
control samples in all cases except for GPD1L (see Figure 26). Figure 27 shows 
comparisons of EXP I and EXP II for the differentially expressed proteins. Even though the 
experiments were carried out using different samples the results seem highly reproducible. In 
EXP I α-enolase, HSPβ2 and unknown protein II were not detectable in control samples 
using the given experiment parameters while they were found at low levels in EXP II (in four 
out of five, one out of five, and two out of five for α-enolase, HSPβ2, and unknown protein II 
respectively). GPD1L was in contrast not detected in DMD samples in EXP II but it was 
found at low levels in two DMD samples in EXP I. Expression of HSPβ2 and α-enolase was 
significantly higher in DMD patients than in control samples in all three experiments, and 
levels of GPD1L and an isoform of troponin T (fast) were significantly lower in DMD patients 
in all experiments. 
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Table 6: Fold-changes and p-values for differentially expressed proteins in DMD  
 
Fold 
Change 
EXPI 
Fold 
Change 
EXP II 
Fold 
Change 
EXP V 
p-value  
EXP I 
p-value  
EXP II 
p-value 
 EXP V 
Average    
Fold 
Change 
HSPβ2  100 8.51 100 8.65E-04 7.31E-04 0.04 8.51* 
unknown protein II 100 8.46 2.00 0.20 0.01 0.37 5.23* 
α-Enolase 100 3.73 3.55 0.03 0.03 0.03 3.64* 
Annexin-A5 2.90 3.57 4.03 0.11 0.02 0.05 3.50 
unknown protein I  3.79 3.35 1.40 0.10 0.01 0.34 2.85 
        
VDAC2 0 0 0 0.09 0.01 0.33 0 
GPD1L 0.29 0 0 0.04 0.01 0.03 0.11 
Troponin T, fast skeletal 
muscle (isoform) 0.11 0.19 0.40 0.01 0.01 0.03 0.23 
* Fold Change 100 in EXP I and EXP V are imaginary values, therefore the average Fold Change was not calculated using this 
value 
 
 
 
 
 
 
 
 
Figure 26: Proteins found to be differentially expressed in DMD. Sample sizes are n=6 for controls, 
n=2 for BMD and n=3 for DMD. Error bars are SEM.  
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Figure 27: Comparison of two 2DE experiments for differentially expressed proteins between DMD 
and control muscle tissue. Error bars are SEM. 
 
 
3.2.3. Expression of candidate DMD markers in LGMD2A and LGMD2I patients 
In order to find out whether the proteins found to be differentially expressed in DMD muscle 
tissue are specifically increased or reduced in dystrophinopathies or rather general features 
of muscle disease the same spots were analyzed in LGMD2A and LGMD2I. An overview on 
fold changes and p-values between control samples and LGMD2A and LGMD2I respectively 
is given in Table 7.  For HSPβ2 the differences between control muscle and other MD 
muscle was not significant. In EXP III, the p-value between control and LGMD2I samples 
was 0.051 indicating a slightly higher HSPβ2 expression in LGMD2I patients. This could not 
be confirmed in a second experiment using different LGMD2I patient samples (see Figure 
28, HSPβ2 section). In EXP V combining LGMD2A and DMD patient samples in one 
experiment the difference between DMD patients and controls as well as between DMD 
patients and LGMD2A patients was significant with an over 15-fold higher average HSPβ2 
expression in DMD than in LGMD2A patients in this experiment (p=0.037 and p=0.040, 
respectively; Figure 28). α-enolase is found at higher levels also in LGMD2A and LGMD2I 
patients, but the mean overall differences to control muscle tissue are not significant. The 
proteins that are found at lower levels in DMD patients (VDAC2, GPD1L, the isoform of 
troponin T (fast), and PEPB1 do not seem show any up- or downregulation in LGMD2A or 
LGMD2I patients. Out of the four proteins that were consistently and significantly differentially 
expressed in DMD patients only HSPβ2 and GPD1L were significantly higher (for HSPβ2) or 
lower (for GPD1L) in DMD patients compared to LGMD2A in the same experiment run (EXP 
IV, see Table 7). α-enolase and the isoform of troponin T (fast skeletal muscle) were not 
differently expressed in DMD patients compared to LGMD2A.  
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3.2.4. HSPβ2 
The goat polyclonal antibody against HSPβ2 was not specific on Western blots and produced 
multiple bands on muscle tissue lysates and also on cell lysates. It was therefore not applied 
on microarrays. Immunofluorescence on C2C12 cells and primary human muscle cells 
(myoblasts and myotubes) resulted in unspecific staining with high background (data not 
shown).  
 
Table 7: Fold-changes and p-values of candidate DMD markers in other muscular dystrophies 
(LGMD2A and LGMD2I). nd: Spot was not analyzeable in the respective experiment. 
 
Fold 
Change 
CONT vs 
LGMD2A 
EXP IV 
Fold 
Change 
CONT vs 
LGMD2A 
EXP V 
Fold 
Change 
DMD vs 
LGMD2A 
EXP V 
Fold 
Change 
CONT vs 
LGMD2I 
EXP III 
Fold 
Change 
CONT vs 
LGMD2I 
EXP IV 
p-value 
CONT vs 
LGMD2A 
EXP IV 
p-value 
CONT vs 
LGMD2A 
EXP V 
p-value 
DMD vs 
LGMD2A 
EXP IV  
p-value  
CONT vs 
LGMD2I 
EXP III 
p-value 
CONT vs 
LGMD2I 
EXP IV 
HSPβ2 2.29 100.00* 15.46 4.43 0.00 0.64 0.42 0.04 0.05 0.42 
unknown 
protein II nd 0.50 3.98 nd nd nd 0.57 0.12 nd nd 
α-Enolase 2.53 1.25 2.85 1.02 3.79 0.41 0.87 0.20 0.96 0.10 
Annexin-A5 0.82 3.08 1.31 1.24 0.88 0.74 0.42 0.68 1.86E-03 0.26 
unknown 
protein I  1.84 0.86 1.63 1.12 2.85 0.33 0.67 0.25 0.71 0.11 
likely VDAC2 1.04 1.04 0.00 0.30 0.89 0.91 0.98 0.42 0.09 0.79 
GPD1L 1.06 1.56 0.02 1.09 0.78 0.84 0.15 0.02 0.78 0.58 
Troponin T, 
fast skeletal 
muscle 
(isoform) 
1.01 0.68 0.58 0.63 0.79 0.98 0.63 0.66 0.35 0.48 
* Fold Change 100 is an imaginary value as in the controls, no HSPβ2 was detected. 
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Figure 28: HSPβ2, α-enolase, GPD1L, and troponin T (fast skeletal muscle, isoform) in LGMD2A and 
LGMD2I (left and middle panels). Right panels are comparisons between controls, LGMD2A and DMD 
patients from the same experiment run. Error bars are SEM. 
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4. Discussion 
4.1. Reverse protein Arrays for Quantification of Muscle Proteins in Muscular 
Dystrophy 
4.1.1. Dystrophin and DGC proteins quantification on reverse protein arrays 
In the present work we assessed a reverse protein array approach for the quantification of 
muscle proteins used in the diagnosis of muscular dystrophies. Tissue lysate reverse protein 
arrays provide a tool to screen for diagnostically relevant marker proteins in a very small 
amount of patient tissue and deliver valuable information for an optional later mutation 
analysis as suggested by Pogue et al. [75].  
 In the muscle tissue lysates used in this study dystrophinopathies were easily and 
reliably detected by the low levels of dystrophin on reverse protein arrays. Similar results 
were obtained in sarcoglycanopathies where a significantly reduced sarcoglycan expression 
on the arrays was seen. Secondary reductions of other DGC associated proteins could be 
measured and quantified with high sensitivity. The three BMD samples in this study showed 
considerable differences in dystrophin expression. For the DYS1 antibody, RFI values 
differed from a DMD-like 0.03 to for the BMD3 sample to an intermediate 0.29 and 0.34 for 
the BMD 1 and BMD 2 samples respectively (mean DMD value: 0.03; mean control value: 
0.93). The BMD 3 patient carried a deletion in exons 48-50 which probably resulted in a more 
severe BMD phenotype as many patients with the same mutation have been reported to 
show a DMD or an intermediate DMD/BMD phenotype [90]. On the other hand, the DYS1 
value of patient DMD 6 was between those of the DMD and BMD samples, which is 
consistent with the clinical presentation of patient who had an intermediate DMD/BMD 
phenotype and is seen as the outlier in the DMD group of the DYS1 boxplot (RFI value 0.09, 
see Figure 7). The splice site mutation (c357+2T>A in intron 5) in the DMD 6 patient has 
been reported to result in a BMD phenotype of variable severity [90, 91].  
Great care must be taken not to misdiagnose primary and secondary deficiencies of 
dystrophin and the sarcoglycans [75]. It is often not possible to clinically discriminate 
between the different LGMD subtypes [92] and even in muscle immunoanalysis, primary 
deficiency in one of the sarcoglycans often cannot be determined unequivocally [93]. Indeed, 
a lower RFI signal for β-sarcoglycan in the LGMD2E sample compared to LGMD2D samples 
was not observed. The LGMD2E sample showed a higher signal for α-sarcoglycan than the 
LGMD2D samples but this is probably of limited relevance given the fact that only one 
LGMD2E sample was included in the study.   
We also showed that the reverse protein array assays worked well using lysates from 
cultured myotubes as the levels of expression using the DYS1, DYS2, and DYS3 antibodies 
were very similar to those from muscle tissue lysates. RFI signals obtained with the DYS1 
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and DYS2 antibodies on myotubes from LGMD2D patients were lower than those on control 
myotubes. Dystrophin was originally not expected to be reduced in LGMD2D [94] but also 
other authors [46, 95] found that dystrophin levels can be reduced in patients with α-
sarcoglycanopathy. This effect was also seen on the tissue arrays but was not significant 
there. As our arrays allow the analysis of any combination of antibodies of interest, it was 
possible to discriminate between cultured cells from DMD and LGMD2D patients as overall 
DYS signals were markedly lower and the α-sarcoglycan signals were higher in DMD cells 
compared to LGMD2D cells even though this was not also significant in our sample set 
including only two samples from LGMD2D patients. Lower γ-sarcoglycan expression in the 
LGMD2C 1 cells compared to the LGMD2D samples was not observed giving further 
evidence that the diagnostic decision on sarcoglycanopathies based on protein analysis 
remains difficult [93].  
To work with myoblast cultures is technically challenging, tedious, and the cell’s myogenicity 
has to be carefully monitored over the entire period of cell culture as we have seen in the 
immunostainings for desmin (see Figure 22). The samples CONT 14 and CONT 15 in Figure 
22 have not been analyzed on reverse protein arrays so a direct comparison of 
immunofluorescence and reverse protein array results can not be made, however the highly 
variable amount of desmin-positive cells in the cultures emphasizes the differences in 
myogenicity that can appear in primary cultures. It is also not clear to which extent myotubes 
from culture represent the phenotype of the muscle including secondary pathogenic 
cascades in muscle tissue. For these reasons, in vitro differentiated myotubes do probably 
not constitute a material that can be applied in diagnostic processes but might play a role in 
preclinical research where many compounds are screened for a possible beneficial effect. 
Furthermore, if a muscle biopsy should be avoided and muscle proteins should be assessed, 
skin fibroblasts transfected with MyoD and expressing muscle proteins might provide another 
interesting amendment of the assay. 
4.1.2. Calpain-3 measurement on reverse protein arrays 
In contrast to dystrophinopathies and sarcoglycanopathies, diagnosis of LGMD2A caused by 
mutations in the gene coding for calpain-3 turned out to be more challenging. Calpains are 
ubiquitous Ca2+-activated proteases (µ-calpain and m-calpain) with calpain-3 as the muscle-
specific isoform. A standard IHC diagnosis of LGMD2A using muscle sections is currently not 
established. Western blot as well as recently evaluated IHC analyses [96] can show normal 
amounts of calpain-3 in LGMD2A patients as a loss of calpain-3 function is not always 
accompanied by reduced protein levels [97]. In our study patient LGMD2A 2 showed 
preserved calpain-3 expression with normal bands in Western blot and a RFI signal on the 
array that was indistinguishable from controls. We saw increased calpain-3 signals in DMD 
patients and in BMD patients even though the latter was not significant and an overall good 
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correlation with Western blots. µ-calpain and m-calpain activity were shown to be increased 
in mdx mice but calpain-3 didn’t contribute to this phenomenon in these experiments [98]. 
The upregulation of µ-calpain and m-calpain is not specific for muscular dystrophy [98, 99]. 
Ueyama et al. [99] found decreased calpain-3 mRNA expression in biopsies from patients 
with progressive muscular dystrophy (two DMD patients, one BMD patient and two patients 
with LGMD) but this effect was not significant. In an earlier study by Spencer et al., increased 
µ-calpain and m-calpain but decreased calpain-3 protein levels in the peak necrotic phase at 
two weeks in mdx mice were shown using an antibody against an epitope that is conserved 
among all three isoforms [100]. In human muscle tissue from DMD patients, calpain-3 was 
found to be reduced only in single cases [76].  
Higher calpain-3 in IHC stainings of immature fibers confirmed by labelling of adjacent 
sections with neonatal MHC have been shown by [97]. As the expression of embryonic and 
neonatal myosin isoforms is considered a characteristic feature of muscular dystrophies 
[101] the higher calpain-3 levels in DMD patients in our study might be an effect of the 
regenerating muscle in DMD patients. General protein degradation in control samples only 
causing an artefact of reduced calpain-3 staining in the controls on the other hand is very 
unlikely according to the results from Western blotting and general protein patterns obtained 
in parallel 2DE experiments. The authors of [97] stated further that the 2C4 antibody yielded 
better IHC/WB correlation than12A2. Generally, experimental artefacts in immunolabelling of 
calpain-3 are quite common as for example thawing of the muscle biopsies or remaining 
mounting medium can lead to false-negative measurements and absence of overall protein 
degradation has to be carefully monitored [76]. Consequently, even though we were able to 
measure calpain-3 levels similar to Western blots on the reverse protein arrays our results 
did not differ significantly between LGMD2A patients and controls or other dystrophies 
suggesting that reverse protein array analysis is not sufficient for the direct detection of 
mutations in the calpain-3 encoding gene. However, we found significantly increased 
sarcoglycan signals (and higher dystrophin expression when using the DYS2 antibody) in 
LGMD2A compared to controls and to other assessed muscular dystrophies suggesting that 
increased expression of these proteins might indirectly help to diagnose LGMD2A when 
using the array.  
4.1.3. Increased desmin expression in development and diseased muscle 
Desmin are class-III intermediate filaments that form a fibrous three-dimensional scaffold in 
cardiac, skeletal and smooth muscle cells. They are circularly arranged at the periphery of Z-
disks keeping adjacent myofibrils laterally aligned and connecting sarcomeres to nuclei and 
to the sarcolemma (reviewed in [1, 102]). Desmin filaments are connected by plectin 
filaments, and the β chain of α-crystallin, a HSP that protects the cytoskeleton from 
mechanical damage [1]. Desmin has therefore an important role in transferring force that 
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occurs during muscle contraction to the entire muscle fiber. Desmin is the main intermediate 
filament protein in adult skeletal and heart muscle with a low concentration in expanding 
myoblasts and satellite cells and a high concentration in differentiated myotubes [103] and 
accounts for 0.35% of total protein in mammal skeletal muscle cells [102]. It is especially 
abundant at the MTJ and at NMJ of skeletal muscle [102]. 
Abnormal accumulation of desmin in muscle fibers is responsible for desmin-related 
myopathies (DRMs) caused by either primary mutations in the desmin gene or familial 
myopathies mapping to the α-B-crystallin gene and other genes (reviewed in [102]). DRMs 
are very heterogeneous diseases with diverse clinical manifestations [103]. DRMs represent 
a exceptional disease state where instead of an absence or reduction of the protein encoded 
by the mutant gene like in other myopathies, an aggregation of the protein is responsible for 
the phenotype. Initially, we considered desmin a candidate normalizing protein for the 
quantification of muscle proteins on reverse protein arrays as many studies it was applied to 
assess the myogenicity of muscle cell cultures [78, 104-106]. Normalization to desmin in 
muscle biopsies was, however, not applicable on the reverse protein arrays as it increased 
the CVs in the sample groups dramatically and also because of the existence of DRMs with 
altered desmin concentrations. In [104], desmin levels at day 0 after seeding were higher in 
DMD than in control cultures. This suggests that DMD myoblasts were more mature due to 
the fact that their progenitor satellite cells had to undergo many more cell divisions than their 
equivalents in normal muscle. However, after equal differentiation time, higher desmin levels 
in DMD myotubes could no longer be seen.   
The mononuclear cells in muscle tissue can undergo repeated cycles of regeneration and 
are activated in muscular dystrophies to proliferation and differentiation upon muscle 
damage. On the molecular level this is seen in the overexpression of genes encoding 
proteins in cytoskeletal microtubules, intermediate filaments (desmin in muscle) and 
microfilaments, especially myosin and actin isoforms that are normally highly expressed in 
neonatal or developing muscle [101]. Higher desmin content in biopsies as was measured in 
on reverse protein arrays is therefore most likely due to regenerating muscle [101] or a 
natural repair mechanism as compensation for the loss of dystrophin [23]. In narrow-pI-range 
2D-PAGE a more intense spot corresponding to desmin was also found in gels from 
DMD/BMD patients.  
4.1.4. Reasons for increased spectrin levels in DMD patients 
Spectrin is the major constituent of the cytoskeleton network under the plasma membrane in 
erythrocytes with muscle-specific β-spectrin isoform that is assumed to be associated to the 
costamere along the sarcolemma [102, 107].  The antibody against spectrin that was applied 
in this study recognizes not only the muscle-specific β-chain of spectrin but also the erythroid 
isoform. Therefore, spectrin RFI signals on reverse protein arrays consisted not only of 
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muscle spectrin but also of erythroid spectrin, which is highly influenced by the amount of 
blood in the muscle biopsy. 2D-PAGE actually showed more intense spots for serum albumin 
as an indicator of blood content in the biopsies of some DMD patients and an overall good 
correlation with RFI signals for spectrin on the reverse protein arrays (see Figure 29). It is 
therefore likely that higher spectrin RFI signals in DMD patients are not a consequence of 
increased spectrin in muscle but of a different amount of blood in the sample. In IHC 
experiments fibers which show negative labeling for both dystrophin and spectrin are 
considered damaged or in early stages of regeneration whereas dystrophin-negative but 
spectrin-positive fibers represent “real” dystrophin abnormalities. In immunohistological 
studies of the plasma membrane the labelling of β-spectrin is often used to monitor 
membrane integrity. In immunohistological intensity measurements, spectrin intensity values 
obtained in control samples using the same antibody as we did on the microarrays were set 
as standard for the calculation of normalization factors [108]. This is however not suitable on 
reverse arrays using whole tissue homogenates and the antibody chosen in our study. As the 
amount of blood in the muscle biopsies cannot be assessed adequately, this normalization 
would render the results of the microarrays very unreliable and thus useless. Furthermore, β-
spectrin levels are higher in slow-twitch muscle (soleus) than in fast-twitch (extensor 
digitorum longus) [109]. As the muscle used for the biopsy in our samples is unfortunately 
unknown in many cases such as DMD 5, we cannot make a statement if higher spectrin 
levels particularly in some DMD samples could be associated tot the higher content of type II 
fast-twitch fibers in the respective muscle. 
 
Figure 29: A: Spectrin RFI signals on reverse protein arrays; B: Corresponding albumin spots on 2DE 
gels. As the SPEC1 antibody applied on the reverse protein array recognizes spectrin in muscle and in 
blood, high spectrin signals in DMD patients (e.g. DMD 5) are probably an artefact of higher blood 
content (represented by intensity of albumin spots). 
 
4.1.5. Normalization of muscle protein levels to muscle “housekeeping” proteins  
Sample drawing from the patient has been shown to be critical in muscle tissue arrays as 
differences in the type of muscle used and the actual proportion of muscle tissue in the 
biopsy can significantly influence the outcome of the assay. Comparisons of protein levels in 
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muscle tissue based on total protein measurements do not account for the varying amounts 
of fibrotic and/or adipose tissue in patients and neither for varying amounts of blood that is 
included while the biopsy is performed. The significantly increased spectrin RFI signals in 
DMD patients (see Figure 9) might for example represent an artefact of differences in sample 
drawing where DMD biopsies incidentally contained more blood than control biopsies. Such 
differences could be accounted for by normalization of tissue from diseased and healthy 
patients using a muscle “housekeeping” protein. A housekeeping protein in general should 
be ubiquitously and constitutively expressed so that signals of proteins of interest can be 
normalized according to it thereby compensating for experimental differences in loading or 
labelling. The application of such housekeeping proteins for signal normalization has to be 
carefully monitored as even in matched tissue samples the relative levels of commonly used 
housekeeping proteins such as GAPDH or β-tubulin [110] and in serum the concentrations of 
common proteins such as albumin or fibrinogen (3.5-5g/dl and 0.2-0.45g/dl respectively) [84] 
or the “normal” concentration of serum CK (reviewed in [111]) in the population vary 
considerably. In our experiments normalization to a muscle-specific protein would be 
particularly suitable because dystrophic muscle contains more connective tissue and fat than 
normal muscle. That’s why differences in muscle proteins could come from the fact that the 
dystrophic biopsies do not contain the same amount of actual muscle tissue. To this end 
other authors have most commonly used MHC [100], in immunoblots by coomassie-staining 
[97, 112], which was not applicable in our study due to extremely high MHC signals on the 
arrays rendering the analysis unreliable. In [61] dystrophin levels are calculated relative to 
laminin-α2 signals assuming that this protein is not affected in DMD patients. β-dystroglycan 
staining for the assessment of protein transfer to immunoblots as in [97] is not feasible in the 
case of DMD/BMD because of secondary reductions that would then lead to false-positive 
results. In myotubes from primary cell culture the myogenicity of the culture should be 
carefully monitored. Normalization to actin in cell lysates is common [84], but remains difficult 
in serum samples, or when biopsies from special tissues are analyzed.  
Normalization to skeletal muscle α-actinin or β-tubulin did not have a great influence on the 
results of the assays and on statistical decisions indicating good overall assay stability. After 
normalization to MHC, on the other hand, even the very clear differences between DMD 
patients and controls could no longer be monitored. It is, however, debatable whether a 
normalization to muscle-specific proteins should be performed at all thereby increasing the 
overall CVs in the sample groups. The fact that dystrophic tissue contains a higher amount of 
fatty and connective tissue contributes to the measurement of lower signals for some muscle 
proteins and might also be regarded as a further hint on the dystrophic processes.  
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4.1.6. Reverse protein arrays – general considerations 
As opposed to gene microarrays, where the probes can be manufactured with a high degree 
of predictability in terms of specificity and affinity reverse protein microarray are probed with 
antibodies that very often lack this predictability [86]. The quality of the results obtained from 
tissue or cell lysate protein arrays depends strongly on the quality of the primary detection 
antibodies used. Antibodies that show unspecific binding to other proteins on Western blots 
are prone to cause false-positive results on reverse protein arrays since this method, similar 
to ELISA, is fully dependent on the specificity of the recognition elements and does not 
deliver further information such as MW of the protein of interest. Therefore, prior to 
application on the microarray, and just as in immunocytochemical methods [15], antibodies 
need to be carefully validated in Western blots (reviewed in [86, 113]). The importance of 
highly specific antibodies became especially obvious in the case of VDAC2. After the 
identification of VDAC2 as a candidate marker for DMD in 2D-PAGE gels, a commercially 
available mouse monoclonal antibody against this protein was applied on reverse protein 
arrays and a significantly lower expression in DMD patients was indeed confirmed on the 
arrays (see Figure 12). In Western blots this antibody produced multiple bands indicating that 
it was not specific for VDAC2 and the results of the reverse arrays were therefore useless. 
Another commercially available antibody produced in goat yielded one single clear band in 
Western blots, however, the effect of lower expression in DMD patients was no longer seen 
on reverse protein arrays. In the case of VDAC2 no confirmation of the results from 2D-
PAGE was possible on reverse protein arrays due to the lack of a suitable antibody.  
The reverse protein array assay format clearly has big advantages over other assay formats. 
As opposed to a sandwich-array depending on two detection antibodies recognizing different 
epitopes it requires only one detection antibody, which is obviously an important feature 
given the difficulty to find highly specific primary antibodies against a high number of proteins 
such as VDAC2 as discussed before. Capture arrays, on the other hand, include a sample 
labelling step, which is technically difficult and often leads to the introduction of experimental 
artefacts. For application of reverse proteins in diagnostic processes standardized, array 
production (spotting of the samples onto the glass substrate) in different laboratories 
represents a major challenge as it is costly and technically difficult. Further standardization of 
assays (including sample drawing and sample preparation) and the development of universal 
references that can be applied across clinical laboratories and time are more big issues 
possibly counteracting a widespread application of reverse protein arrays in clinical 
proteomics or diagnostic procedures [86]. An ideal universal reference would serve as a 
positive control for antibody specificity and staining procedures, be fully renewable, and still 
resemble the test samples to the biggest possible extent. For human tissue samples this is 
practically not feasible as normally only very limited sample sizes are available, and even 
lysates from cell lines do not overcome the problem of long-term reproducibility. However, 
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this problem is not unique to reverse protein arrays but exists also in Western blotting or IHC 
assay procedures. Alternatively, immunogenic peptides might serve as highly reproducible 
and renewable internal standard [86].  
In conclusion, our results show that the quantitative measurement of dystrophin and DGC 
proteins in muscle tissue and cultured myotubes can be carried out in a reverse protein array 
format. The saving of sample material is a great advantage over currently used methods 
such as Western blotting or IHC, in particular when numerous biopsies are to be analyzed for 
a wide range of proteins thus providing an excellent tool to collect valuable and 
comprehensive information about proteins and protein patterns in patient samples. The 
analysis of a wide range of proteins in small tissue samples might be of particular interest in 
the assessment of therapeutic effects on the protein level in clinical trials where biopsies 
have to be repeated after treatment such as exon skipping therapies [61]. 
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4.2. 2DE / HPLC-MS/MS proteomic profiling of DMD skeletal muscle tissue  
 
The loss of sarcolemmal integrity in DMD patients appears to cause various downstream 
effects in metabolic pathways and cellular signaling. The application of 2DE and MS aims at 
the elucidation of these downstream effects in order to find new disease markers for 
diagnostic purposes and for the monitoring of preclinical and clinical trials. As mass-
spectrometry based proteomics experiments are considered poorly reproducible, especially 
in combination with preceding 2DE separation, we have first performed analyses of landmark 
spots on representative gels from human skeletal muscle tissue in order to compare our 2-D 
maps to reference maps from literature. Our overall protein pattern corresponded well a 
reference map for human vastus lateralis [114]. Prefractionation using the ZOOM isoelectric 
fractionator did not increase the resolution in the first dimension but rather caused horizontal 
streaking and overall higher background staining and was therefore omitted in subsequent 
experiments. We have found 500-1000 spots on each silver-stained gel which is consistend 
with the general conception that conventional gel stains such as Coomassie or silver stains 
normally visualize around a few hundred protein spots [114]. Most sophisticated DIGE 
approaches are probably capable of presenting a few thousand spots in one single 
experiment [82, 85]. The dynamic protein range in In a study using dialysis-assisted two-
dimensional gel electrophoresis (DIGE), a dynamic range of protein expression of about 
1000 was seen in over 1000 spots [78]. In our 2DE experiments using silver staining we have 
seen a slightly higher dynamic range (about 3000), however, we detected lower total spot 
numbers. 
In our 2DE experiments we have found four differentially expressed proteins in DMD tissue 
that were reproducible in our experiment series. Evidence that the differences in protein 
expressions for these proteins are “real” differences between DMD and control tissue 
samples comes from the fact that in the two BMD samples intermediate spot intensities are 
measured (except for HSPβ2  where like in DMD samples no protein was detected, and for 
GPD1L where the protein level was slightly higher in DMD than in BMD). This might to a 
certain extent compensate the problem of unmatched tissue samples of often unknown 
muscle origin in our study as the BMD phenotype represents a milder disease progression of 
DMD similar to different stages of a disease as suggested by Schiess et al. in order to follow 
disease progression [115]. HSPβ2 and GPD1L appeared particularly interesting because 
their differential expression in DMD patients was not seen in either LGMD2A or LGMD2I and 
are therefore discussed in detail below.  
4.2.1. HSPβ2 in DMD and HSPs in muscular dystrophies 
We have found HSPβ2, a 20.2kDa member of the sHSP family to be dramatically increased 
in DMD muscle compared to controls (>8.51 fold). The protein was mostly not detectable on 
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2DE gels from control muscle tissue and it was not significantly increased in other muscular 
dystrophies. In particular, we have seen a significantly higher expression in DMD muscle 
than in LGMD2A muscle when the two diseases were compared in the same experiment run. 
HSPβ2, therefore, represents a candidate disease-specific marker of muscle degeneration in 
DMD and BMD patients. HSPβ2 was not identified on 2DE gels in previous studies on mdx 
skeletal muscle tissue [82] or human vastus lateralis muscle [114].  
 
Other HSPs identified in our experiments on the 2DE gels include α-crystallin β chain HSP27 
(HSPβ1, in two isoforms), and HSP90-β (HSP84). The authors of [82] state that decreased 
HSP90 in mdx mice might be associated with impaired cell growth. We could, however, not 
find differential expression of HSP90 in muscle tissue from DMD patients.   
Generally, the transcription of HSPs is induced by cellular stress (such as “heat”, 
differentiation, growth, oxidative stress, ischemia, etc.). HSPs can be divided into five major 
families: the four high-molecular-weight families HSP100, HSP90, HSP70, HSP60, and the 
large family of small heat shock proteins (sHSPs) characterized by an α-crystallin domain of 
about 100 amino acids [116]. Many HSPs are molecular chaperones involved in the 
prevention of aggregation of misfolded proteins but also in intracellular protein transport. In 
muscular dystrophies HSPs are believed to play this dual role by targeting denatured or 
misfolded muscle proteins thereby initiating cellular repair and by chaperoning newly 
synthesized muscle proteins during regeneration. In many pathological processes the up-
regulation of stress factors is a response to cellular injury. Muscle cells in general are 
frequently exposed to severe cellular stresses caused by mechanical stress during activity 
and exercise and therefore must be protected from damage by specialized mechanisms such 
as HSPs. Skeletal muscle in muscular dystrophy patients is particularly subjecte to constant 
severe conditions from sarcolemmal instability and HSPs have been found to be differentially 
expressed in a number of diseases and experiments: Doran et al. [82] found drastic increase 
(8.09 fold) in cardiovascular HSP (cvHSP) in mdx mice and examined also other key HSPs 
(HSP20 (!) , HSP25 (-) (equal to HSP27 in humans [117]) , HSP60 (-), HSP70 (-) , HSP90 
(!), HSP110 ("), GRP75 (!)), but not HSPβ2. cvHSP was also found to be increased in 
aged gastrocnemius muscle from rats by immunoblotting indicating that stress response and 
muscle degeneration correlate, however, it was in this study not possible to identify the 
corresponding spot in a 2DE gel by MS [118]. Other differences in expressions of HSPs 
include induction of HSP70 due to muscle necrosis (reviewed in [117]) and oxidative stress 
[119], HSP47 upregulation in membranes of regenerating muscle in various muscular 
disorders [112], induction of other stress proteins such as GRP due to high calcium 
concentration (discussed in [120]), increased levels of HSPβ1 during myotube differentiation 
[78]  and increased levels of p20 (HSPβ6) and HSP27 associated with high muscle activity in 
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fast-twitch muscles in dy mice [120]. HSP27 and α-crystallin β chain levels are generally 
higher in slow-twitch than in fast-twitch muscle [117] giving further evidence on the 
importance of matched muscle samples for the evaluation of candidate marker proteins. 
HSP90 and HSP27 bind to actin and might therefore have a stabilizing actin filaments in 
muscle cells and mitochondrial HRPs have an important role in skeletal muscle metabolism 
(reviewed in [117]). Most of the members of the small HSP family mediate stabilisation of 
cytoskeletal protein folding and transport. If these proteins are upregulated, it appears that 
damaged muscle fibers attempt to rescue cellular integridy via modulation and repair of the 
cellular network [82]. Α-crystallin β, HSP27 and other sHSPs are induced in differentiating 
skeletal muscle under the influence of MyoD, and HSP27 and HSP70 are induced in skeletal 
muscle after exercise (reviewed in [117]).  
HSPβ2/MKBP was identified at the same time by two independent groups [121, 122]. 
It was suggested that two independent stress response systems for muscle maintenance and 
differentiation based on oligomerization properties coexist [123]. The authors conclude that 
the system consisting of HSP27/αB-crystallin/p20 is induced by heat and/or other stresses 
while the system consisting of HSPβ2 and HSPβ3 may work dominantly under normal 
conditions and does not show heat inducibility. The authors hypothesize further that HSPβ2 
interacts directly with myofibrils (localization not only at the NMJ where DMPK is localized 
but also at the Z-band of myofibrils) and contributes to myofibril integrity. The complex of 
HSPβ2 and HSPβ3 was indeed shown not to interact with other sHSPs, while HSPβ2 alone 
can interact with HSP20 independent of HSP27 and αB-crystallin [121, 124]. The 
HSPβ2/HSPβ3-complex has very low chaperoning activity [124] but HSPβ2 alone associates 
specifically with DMPK and protects it from heat-induced inactivation [121]. Interestingly, 
DMPK expression increased dramatically upon exercise-induced muscle damage in a gene 
expression profiling study [125]. Though HSPβ2 expression does not seem to be heat 
inducible it behaves like a stress-responsive protein when after heat treatment, a 
redistribution of protein to the insoluble cell fraction takes place [121].  
HSPβ2 is expressed in skeletal and heart muscle [122] and possibly to a lower extent in 
prostate, testis, ovary, intestine, and colon tissue (mRNA, [123]). In pig muscle HSPβ2 and 
cvHSP are expressed in heart and muscle only [126]. HSPβ2 expression is induced during 
the initial phase of skeletal muscle differentiation but still later than αB-crystallin [123]. The 
authors showed in the same study that the induction of HSPβ2 upon serum depletion in 
muscle cells is actually the result of myogenic differentiation and not due to the stress 
stimulus caused by the serum removal. In pig developing muscle HSPβ2 temporally 
increased the first day after birth and then showed a developmental expression of 
upregulation with age [126], HSPβ2 stains only differentiated multinuclear myotubes in IHC, 
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but even after pre-treatment with 0.5% Triton-X which worked for HSP27 and αB-crystallin no 
filamentous localization could be detected [123].  
In myotonic dystrophy type 1 (DM1) an abnormal expansion of CTG repeats in the 3’ 
untranslated region of the dystrophia myotonica protein kinase (DMPK) causes face-, neck, 
and distal-dominant limb weakness and atrophy with decreased expression of DMPK. 
Histologically, there are only few necrotic and regenerating fibers [127]. The accumulation of 
mutant RNA containing the CUG repeats interferes with alternative splicing of several genes 
such as the insulin receptor or chloride channels contributing to clinical features of DM1. ER 
stress was suggested to be involved in the muscle wasting seen in DM1 but disrupted 
intracellular Ca2+-homeostasis did not seem to be the only reason for it. HSPβ2 was found to 
be increased about 2.5 folds in Western blots in DM1 patients but not in patients suffering 
from polymyositis [121], indicating a specific change in HSPβ2 that does not result from 
muscle degeneration itself. Our results suggest, however, that an increase in HSPβ2 due to 
muscle degeneration cannot be excluded and further experiments on HSPβ2 expression in 
muscular dystrophies should be carried out.  
4.2.2. Lower GPD1L expression in DMD/BMD patients 
A protein that was identified as GPD1L at the mass spectrometry facility at the Biozentrum in 
Basel was found to be significantly reduced on 2DE gels in DMD patients with an average 
fold-change of 0.11 while not showing any differential expression in either LGMD2A or 
LGMD2I patients (see Figure 28). We have, however, not been able to identify this protein 
mass spectrometrically in our laboratory with the given instrumental setup.  
Mutations in the GPD1L gene are the cause of Brugada syndrome type 2 [128] and a cause 
of sudden infant death syndrome [129]. Brugada syndrome is a rare autosomal-dominant, 
male predominant form of ventricular fibrillation characterized by ventricular arrythmias, 
syncope, a high incidence in sudden deaths, and coved-type ST-segment elevation in the 
right precordial leads of the electrocardiogram (ECG, reviewed in [128]). Mutations in the 
SCN5A (encoding for the α-subunit of the heart sodium channel) have first been linked to 
Brugada syndrome and then a second locus on chromosome 3 was identified in a single 
pedigree with a progressive conduction disease and a relatively good prognosis, later being 
identified as GPD1L [128, 130]. Most known mutations for Brugada syndrome decrease 
inward Na+ current, and mutations in the cardiac Ca+ channels that decrease inward Ca2+ 
current have been shown to cause similar symptoms. In general, only ion channel-related 
genes have been shown to cause Brugada syndrome. Arrythmias and ST elevations are 
likely to be caused by inadequate depolarizing current in the epicardium of the left right 
ventricle where the transient outward repolarizing current is greatest [131]. ECG 
abnormalities that can lead to ST-segment elevations are also seen in DMD patients [128, 
132]. 
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GPD1L is concentrated in the membrane fraction in heart tissue (most highly expressed) and 
at lower levels in skeletal muscle, kidney, lung, and some other organs [131].  For the heart 
sodium channel SCN5A, the A280V mutation in GPD1L decreased inward Na+ current, but 
this does not hold true for the skeletal muscle sodium channel SCN4A. Surface expression of 
SCN5A (but not total SCN5A protein) was reduced by almost 50% by the A280V mutation in 
GPD1L. No direct interactions between SCN5A and GPD1L could be shown though [131].  
On the protein level, GPD1L has to our knowledge not been shown to be reduced in DMD 
patients. GPD and GPD1L RNA levels were shown to be changed 0.63 and 0.54 fold 
respectively in muscle biopsies from young DMD patients [133]. A study on microRNAs in 
skeletal muscle tissue found a two-fold increase in microRNA targeting GPD1L resulting in a 
predicted two-fold reduction in GPD1L RNA in DMD patients [134]. On the other hand, an 
increase in GPD RNA was measured in rabbit muscle after denervation due to accumulation 
of white adipose tissue [135]. The authors of this study stated that the denervation of muscle 
followed by the development of white adipose tissue in fast but also in slow-twitch muscle 
could represent an interesting model for myodystrophic diseases with fatty degeneration of 
muscle tissue. Unfortunately, the commercially available goat polyclonal antibody against 
GPD1L that we have evaluated in order to confirm the results from 2DE by Western blotting 
and/or reverse protein arrays proved to be highly unspecific and produced multiple bands in 
Western blots. GPD1L might not be particularly suitable as a diagnostic marker because an 
absence or reduction in protein levels in the disease state is more challenging to monitor 
than an increase and suitable positive controls have to be carefully evaluated. However, it 
would be interesting to analyze the role of GPD1L in the molecular pathways underlying 
muscular dystrophies in order to find out whether GPD1L reduction is a decisive secondary 
factor responsible for the DMD phenotype and particularly cardiac involvement.  
4.2.3. Other candidate markers found to be differentially expressed in DMD patients 
The significant increase in α-enolase in DMD patients that was seen on 2DE gels has been 
observed to a lesser extent also in other muscular dystrophies. The glycolytic enzyme 
enolase consists of three tissue-specific isozyme subunits (α/β/γ) forming homo- (α/α in 
embryo and most adult tissues, β/β in striated muscle, γ/γ in neurons) and heteordimers (α/β 
in striated muscle and α/γ in neurons). During ontogenesis in muscle, a transition from the 
embryonic α/α isoform to the α/β and β/β isoforms takes place with a precise organization of 
the β-enolase expression according to the energy requirements in the different muscle fiber 
types [136]. In fast type IIB fibers expression of β-enolase was highest, intermediate in type 
IIA and IIX, and lowest in slow type I fibers [136]. Muscle-specific β-enolase (ENO3) mRNA 
was found to be changed 0.64 fold in DMD patients whereas α-enolase (ENO1) was found to 
be changed 1.70 fold [133]. On the protein level it was seen that during the differentiation of 
human myoblasts the expression of ENO3 increased dramatically [78]. Myoblasts from fetal 
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tissues have been shown to express predominantly α-enolase whereas myoblasts from 
postnatal tissues express mostly β-enolase [137]. Therefore, higher levels of α-enolase in 
DMD patients that are also seen on 2DE gels of other muscular dystrophies (see Figure 28), 
probably come along with the fact that fetal-like isozyme patterns are frequently observed in 
neuromuscular disorders, particularly in severe forms [138]. The isozyme pattern found for 
enolase in [138] was, however, fetal-like in only one out of four DMD cases and intermediate 
in two out of four. This might have occurred due to the fact that the biopsies did not really 
show the typical regenerating fibers which gives further importance of sample drawing from 
the patients and controls. 
 
The isoform of troponin T from fast skeletal muscle that we have found to be reduced in DMD 
patients was also slightly reduced in LGMD2A and LGMD2I (see Figure 28) and might 
therefore represent a general indicator of muscle damage. As we have identified this protein 
in more than one spot on the 2DE gels more than one isoform is obviously present in skeletal 
muscle from muscular dystrophy patients. Different isoform patterns in muscle can either 
represent different contractile properties of the muscle types used in the experiments as for 
example the characteristic patterns of myosin and tropomyosin in deltoideus and vastus 
lateralis muscle [139] but may also constitute possible novel markers of muscle disease. 
However, highly specific antibodies recognizing only one isoform would be needed if isoform 
patterns are to be taken into consideration as diagnostic approach for example on reverse 
protein arrays.   
 
We have also found annexin-A5 to be increased 3.5 fold in DMD patients compared to 
control samples. Only a slight increase was was seen in LGMD2I patients and conflicting 
results were obtained in two experiments analyzing LGMD2A patients.  
Annexins are Ca2+/lipid-binding proteins with a highly conserved protein core and variable 
domains at the N-terminus [140]. Annexins exert different physiological functions mostly 
related to their membrane-binding properties as membrane-membrane or membrane-
cytoskeleton linker. Annexin-A1 and annexin-A2 play a role in dysferlin-mediated membrane 
repair [11] and show higher expression in dysferlinopathies [141]. The positive correlation of 
annexin A1 and A2 levels with clinical severity in LGMD2B but also in DMD and BMD 
patients indicates that they might be prognostic markers of disease [141].    
Annexin-A5 can form calcium channels and mediates calcium-dependent apoptosis as well 
as probably the Ca2+-uptake in hypertrophic chondrocytes  [140, 142]. It assumedly plays a 
role in skeleton growth and development which was however not confirmed in an experiment 
generating an annexin-A5 deficient mouse model [140]. The facts that annexin-A5 is an 
intracellular protein that can be secreted and is also found in blood [140] and it was reported 
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to be increased almost six-fold in DMD patients in a gene expression study [101] make it a 
valuable candidate in the panel of candidate indicators of disease severity in DMD and other 
muscular dystrophies. 
 
We have furthermore found a protein that was identified as VDAC2 at the Biozentrum mass 
spectrometry facility to be completely undetectable on 2DE gels from DMD muscle tissue, an 
effect that has not been seen in LGMD2A or LGMD2I. MS-analysis in our laboratory failed to 
confirm this result, and the position of the spot on the gel is not fully compliant with VDAC2 
MW and pI. VDACs are mitochondrial outer membrane proteins and exist in three isoforms 
(VDAC 1, 2, 3). VDAC1 is localized in skeletal muscle of mice and humans in the SR and 
mitochondria where VDAC1 antibodies and Mitotracker stained virtually identical regions but 
not in the sarcolemma [143]. In Western blots no differences in VDAC1 expression could be 
demonstrated between control and mdx mice. As at the time of this study specific antibodies 
against VDAC2 and VDAC3 were not available the authors carried out Northern blots of total 
RNA after RT-PCR and found no significant changes for both VDAC1 and VDAC2 between 
control and mdx mice except for a slight reduction in 90-days old mdx mice with respect to 
their age-matched controls. In contrast, VDAC3 was markedly reduced in mdx mice in all age 
groups tested. Due to the very high sequence homology between VDAC1, VDAC2 and 
VDAC3, the preparation of specific antibodies against either one of the VDACs seems to be 
very challenging. Yamamoto et al. [144] tried to produce specific antibodies against the three 
rat VDACs (30.6, 31.6, and 30.7 kDa for VDAC1, 2 and 3 respectively) but were not 
successful except for VDAC1. Furthermore, they found that recombinant VDAC1 and VDAC2 
show a very similar migration pattern in SDS-PAGE and VDAC3 unexpectedly seems to 
migrate slightly faster. VDAC1 was the most abundant isoform in the mitochondria of all 
tissues examined but considerable differences in relative levels between tissues were found 
and they did not analyze skeletal muscle. VDAC1 and VDAC2 were divided into three and 
two spots in their 2-DE experiments. Antibody specificity is obviously an issue for VDAC1, 2 
and 3 respectively. It is hard to make a statement on VDAC2 levels in control versus patient 
samples in western blots because of the very high sequence identities of all VDAC isoforms. 
BLAST (bl2seq) alignments [145] using compositional score matrix adjustment [146] show 
74% identity (91% positives) between VDAC1 and VDAC2, 67% identity (85% positives) 
between VDAC 1 and VDAC3 and 73% identity (88% positives) between VDAC2 and 
VDAC3. The commercially available VDAC2 (a) antibody from abcam was produced using 
GST-tagged recombinant full length human protein as antigen. VDAC2 (b) was produced 
against a synthetic peptide corresponding to the C-terminal amino acids 298/309 of Human 
VDAC2. BLAST predicts for the length of the peptide 66% identity (83% positives) with 
VDAC1 and 83% identity (83% positives) with VDAC3. Gene expression profiling studies 
 78 
showed a 0.55 fold change reduction in VDAC1 [133] in RNA extracted from muscle biopsies 
from young DMD patients (under two years, however, four- and five-year-old patients did not 
show different expression patterns) and a -2.5 fold change in VDAC1 pseudogene in muscle 
biopsies from 5-7 year old males [101].  
Despite these obvious challenges to produce specific antibodies against VDACs, the marked 
reduction in DMD patients makes them an interesting candidate disease marker. 
Mitochondrial oxidative phosphorylation is impaired in DMD and mitochondrial proteins are 
largely reorganized. Elevated intracellular calcium and subsarcolemmal calcium levels have 
been found to be increased in muscle cells/muscle fibers from dystrophic mice. Mitochondria 
in muscle cells undergo a so-called “permeability transition” in response to persistent 
elevated calcium concentrations. In a regulated process, a large pore complex spanning the 
inner and outer mitochondrial membrane is formed which leads to loss of matrix and 
intermembrane content and swelling of the mitochondria. If this process is not stopped, 
mitochondria eventually break apart and cause necrotic and/or apoptotic cell death. This 
raises the question whether absence of the spot likely representing VDAC2 on the DMD 2DE 
gels is a secondary consequence of general lower expression of mitochondrial proteins in 
DMD patients as seen for example in the tissue-specific downregulation of eight 
mitochondrial mRNAs in mdx mice [147]. As seen in Figure 30, other mitochondrial proteins 
such as mitochondrial ATP synthase or mitochondrial malate dehydrogenase that we have 
identified on 2DE gels do not reflect the absence of VDAC2 in DMD patients indicating that 
the possible reduction in VDAC2 in DMD is more specific than just reduction in overall 
mitochondrial protein. Moreover, HSPβ2 has an association with mitochondria that is 
enhanced by head shock (and probably other cellular stress) [148] and the strong increase in 
HSPβ2 levels that we have seen in DMD patients would also not conform to the hypothesis 
of overall mitochondrial protein reduction. Further investigation on the drastic reduction of 
VDAC2 and probably other VDACs on the protein level should include first of all the definitive 
identification of the corresponding spot on the gel as VDAC2 and the evaluation of suitable 
antibodies. 
 
Two unknown proteins were furthermore found to be differentially expressed in DMD patients 
compared to healthy controls. We have so far not been able to identify these proteins mass 
spectrometrically. In order to get the complete picture of candidate novel markers it would be 
interesting to identify the proteins corresponding to the respective spots in the 2DE gels.   
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Figure 30: Mitochondrial proteins in DMD patients. Left panel: Position of mitochondrial proteins on 
gel. Right panel: VDAC2, ATP Synthase (mitochondrial) subunits alpha and beta, and malate 
dehydrogenase (mitochondrial) in EXP II, mit=mitochondrial, error bars are SEM. VDAC2 absence is 
probably not an effect of lower mitochondrial number. 
 
4.2.4. Considerations on sampling  
For the interpretation of the changes found between normal and diseased tissue it is 
necessary to rule out the possibility that differences might be caused by sample properties or 
characteristics rather than by the primary genetic mutation. The expression of genes on the 
mRNA level changes along the progression of the disease [133]. This might be evidence that 
by comparing controls with patients (not age-matched) some early markers of DMD could be 
missed. On the other hand, the same authors report that most of the molecular aspects seen 
in the pathophysiology in DMD are already seen in very young infant patients. Muscle protein 
levels and isoform patterns are strongly dependent on muscle innervation (reviewed in [85]): 
The loss of the connection of a muscle fiber unit to its motor neuron causes atrophy whereas 
artificial electro-stimulation causes considerable changes in muscle activity and fiber type 
shifting is observerd in various neuromuscular disorders and as adaptions to functional 
requirements in normal muscle tissue. Moreover, it was shown previously that the patterns of 
contractile protein isoforms in vastus lateralis and deltoideus muscles are reflective of their 
relative contents of fast- and slow-twitch muscle fibers [139]. A a number of proteins 
associated with glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation have 
been shown to be increased in vastus lateralis and the authors associate this phenomenon 
to the greater metabolic potential of vastus lateralis compared to deltoideus. Mitochondria 
are more abundant in slow-twitch (type I) muscle than in fast-twitch (type II) muscle [1] and 
oxidative enzymes are typically more abundant in slow-type muscle than in fast-type.  
For dystrophin deficiency and in DMD/BMD patients the effect of muscle type in the biopsy 
does not seem to be significant [109], no considerable differences were found between a 
biopsy from the quadriceps taken at the time of the diagnosis and two follow-up biopsies 
from both the left and the right extensor digitorum brevis ten years later [108]. Dystrophin 
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deficiency is obviously such a dominant effect that muscle fiber differences in the samples do 
not have a considerable influence the outcome of analyses. This might be different for 
candidate marker proteins serving for the elucidation of secondary pathobiochemical 
abnormalities in DMD musce. Fast muscle fibers generally tend to be more affected in DMD 
patients than slow-twitch [149]. As a relevant proportion of our sample set consists of 
biopsies from unknown muscles alterations in protein patterns might be influenced by the 
muscle type that in the worst case would outbalance the alterations caused by the disease. 
The relative amount of fast- and slow-twitch fibers in muscle biopsies varies not only 
depending on the muscle that is used for the biopsy but also on the region (deep or 
superficial) of the muscle [2], a variable that is impossible to control in our study. From the 
samples with a known origin muscle none was a biopsy from typical type I-fibre muscle such 
as the soleus from a typical type II-fibre muscle such as orbicularis oculi. Samples in our 
study consisted of some vastus lateralis (depending on the region of the biopsy between 58 
and 70% type II fibers), deltoideus (40-50%), biceps brachii (50-58%), tibialis anterior (27-28) 
[2] and quadriceps femoris. For HSPβ2 expression for example the only case where the 
protein was detectable (at a low level) in a control sample on a 2DE gel was sample CONT 5 
which is from tibialis anterior. In EXP V in sample CONT 2 consisting of tibialis anterior 
muscle, no spot corresponding to HSPβ2 was detected whereas in the same experiment in 
DMD 12 (tibialis anterior) increased HSPβ2 was found. This suggests that in the case of 
HSPβ2 muscle fiber type differences probably not account for the higher protein levels in 
DMD patient tissue. Consequently, including the differences that come from the fact whether 
the muscle biopsy is from deep or superficial muscle biopsy it is not likely that the hardly 
assessable type of muscle used in our samples account for all of the differentially expressed 
proteins that we have found. However, in further studies aiming at the validation of markers 
of disease, samples should be matched as good as possible as a common problem to many 
approaches in clinical proteomics (utilizing eiter body fluid or tissue samples) is the assembly 
of a sample set from clinically well-defined individuals [84].  
4.2.5. Proteomic approaches to (muscle) biomarker discovery 
Functional genomic studies applying methods as DNA microarrays and profiling the 
transcriptome make the assumption that changes on the mRNA level are directly reflected in 
the proteome. This might not always be true, for example if protein levels are determined by 
the rate of their degradation or if changes are due to protein modifications (reviewed in [81]). 
Furthermore, rather than from changes in gene expression many short-term changes in the 
proteome originate from protein modifications such as phosphorlyation or acetylation 
representing the actual phenotype or disease state of the organism. Proteomic approaches 
aim at the evaluation of protein patterns in order to understand pathways and mechanisms 
underlying diseases, therapeutic strategies, and the discovery of new biomarkers. 
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Biomarkers are not only applied in diagnostic procedures but also in research processes and 
clinical trials, when therapeutic potential of novel drugs or treatments should be assessed. 
However, the process of biomarker discovery is lengthy and cost-intensive and in many 
cases many candidate biomarkers do not reach validation due to lack of specificity or 
sensitivity. Many proteins are identified and classified as potential biomarker but the problem 
remains that potential biomarkers reported by one group of researchers are not identified by 
other groups, even though if they are using similar methods [84, 150, 151]. We have for 
example not identified adenylate kinase that was reported to be dramatically decreased in 
mdx skeletal [82, 152]. It is of course possible that this decrease in mdx mice is not seen in 
humans as to our knowledge a decrease in adenylate kinase has not been observed in 
proteomic studies or in gene expression analysis [101]. Desmin was found to be increased in 
mdx diaphragm 2.14 fold [82] and 2.1 fold [83] and desmin upregulation is a known feature of 
dystrophinopathies. We have not found desmin to be significantly increased on our 2DE gels. 
The gels obtained after ZOOM isoelectric prefractionation revealed higher desmin 
expressions in the DMD patients included in the experiment, however, as there was only one 
gel from pooled DMD samples and controls respectively we cannot make a statement on 
significance (see Figure 31). In any case, these observations emphasize the need for careful 
evaluation and validation of candidate marker proteins that are found in 2DE experiments. 
There is a risk of generation of low-quality data increasing “background noise” in biomarker 
discovery rather than contribution to real progress in clinical proteomics if candidate 
biomarkers are not validated. A potential way out of this situation is the validation using 
independent assays such as ELISA, quantitative Western blotting, and confocal microscopy  
[23, 84].  
MS-based proteomics have become the method of choice for many comparative and 
exploratory investigations in biological sciences. The accessible part of the proteome in 
serum or tissue at a given time or disease state is often separated prior to MS-based  
 
Figure 31: Higher desmin expression in DMD patients compared to control muscle tissue. A: Spot 
corresponding to desmin on narrow-range pI 2DE gels from control and DMD muscle tissue. B: 
Reverse protein array (RPA) RFI from the same samples that were pooled in A; C: Desmin spot 
intensities from 2DE gels in EXP II. No significant differences for desmin spot intensities or RFI signals 
on reverse protein arrays were found in DMD samples.  
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analytical methods, most commonly fractionated by chromatography and/or gel 
electrophoresis in order to reduce sample complexity. Fractionation methos such as 2DE 
again have a number of limitations. Skeletal muscle in particular consists of extremely large 
cellular structures as well as a considerable amount of insoluble proteins and it is relatively 
tough for preparing cell extracts [83, 85]. Proteins that are present at low concentrations can 
be hidden by highly abundant proteins or simply not detectable by the staining method of 
choice. It has become widely accepted that in order to identify diagnostic biomarkers the 
dynamic range of the samples included in the discovery experiment has to be reduced [84, 
115].  Prefractionation methods have been applied in a number of studies in order to remove 
highly abundant proteins that are masking underlying less abundant spots or in order to 
expand the dynamic range of detection. However, all these procedures by their nature 
possibly introduce artefacts to subsequent analysis. In addition, by removing highly abundant 
serum proteins (e.g. albumin) other potentially interesting compounds bound to these 
proteins can be removed in the same step and therefore be missed in subsequent analyses 
[84]. In serum samples immunodepletion did so far not lead to the desired increased 
discovery of low-abundance biomarkers due to the introduction of variability in sample 
preparation. We carried out a prefractionation step according to isoelectrical point and the 
subsequent analyis of narrow-range pI fractions on separate gels did not lead to higher 
resolution but rather to higher background staining and horizontal streaking on gels. This was 
most possibly due to protein degradation in the time-consuming experiment with many steps 
carried out at room temperature. Another disadvantage of the prefractionation of the complex 
protein sample in solution is the relatively high sample consumption. For the ZOOM 
isoelectric fractionator an amount of 1.95mg total protein is necessary for one fractionation 
run which is hardly obtainable from a single patient (when lysing a large biopsy of 15-20mg, 
resulting amounts of protein in the lysate are around 1.5mg [114]). We therefore omitted 
prefractionation steps in subsequent experiments to obtain the most complete information 
about protein alterations in skeletal muscle tissue from patients with various muscular 
dystrophies compared to controls.  
The range for plasma protein concentrations comprises about 12 order of magnitude from 
classical serum proteins (>10mg/ml) to interleukins and cytokines (<pg/ml). Tissue leakage 
proteins are found at concentrations around ng/ml [153] already presenting a major 
challenge to currently used technologies and methods aiming at biomarker discovery. 
Prostate specific antigen (PSA), probably the best known biomarker for the detection of 
prostate cancer, would be assumed to be present in blood due to tissue leakage at a 
concentration about 1000fold lower than in the prostate just because of the volume 
difference of the organs [115]. It was stated relatively early that elevated levels of serum CK 
do not directly reflect a change in the gene expression pattern [138], but the presence of the 
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MB isozyme in muscle is caused by regenerating muscle and the elevated serum CK is 
caused by leakage from damaged muscle. Advantages of biomarker discovery in tissue, on 
the other hand, include a more “direct” contact to the actual site of disease the disease and 
an overall lower range of protein concentrations in tissue (reviewed in [115]).   
To overcome the high complexity of biological samples targeted approaches focus on a 
subproteome, e.g. on proteins that are N-linked glycosylated (reviewed in [115]) or in skeletal 
muscle on Ca2+-binding proteins rather than on global protein expression patterns [56], while 
new emerging MS-based technologies as selected reaction monitoring (SRM, also referred 
to as multiple reaction monitoring, MRM) are promising new approaches for the sensitive 
detection of pre-defined analytes in complex samples [115].  
The extent of the difference between controls and patient samples that is considered a “real” 
different is often discussed in literature. A two-fold increase or decrease in protein expression 
on 2DE gels is usually called relevant. The degree of experimental variation that is 
introduced in a 2DE experiment is at least 20% in terms of average CV and another 25%-
50% comes from the biological variation depending on sample origin [154]. As biological 
variation in our sample set is hard to assess we have consideret a threshold of four-fold 
increase or decrease in protein expression relevant in our 2DE experiments.  
4.3. Conclusions and Outlook 
In conclusion, we have identified a set of candidate marker proteins that could after validation 
be applied in future diagnostic processes or in the monitoring of success in clinical trials 
evaluating emerging therapeutic approaches to muscular dystrophies. In case the highly 
sensitive antibodies to the respective proteins are available, assays could be carried out in a 
reverse protein array format that we have evaluated. Bringing a candidate biomarker to the 
level of a validated disease or even diagnostic marker is an ambitious goal and faces many 
methodological challenges. As muscle tissue is not readily obtainable future efforts that aim 
at the identification of biomarkers for muscular dystrophies in serum rather than in tissue are 
particularly interesting. In mdx serum coagulation factor XIIIa has been identified as a 
candidate marker of muscular dystrophy [155]. In the simplest case higher peak intensities in 
mass spectra might be characteristic for dystrophic sera like it is the case for serum CK. 
Whether factor XIIIa constitutes a serum biomarker for dystrophinopathies in humans 
remains to be demonstrated in translational studies where its specificity also needs to be 
addressed.  
The concept of muscle-specific proteins are detectable in serum due to muscle damage is 
well known and provides the rationale for routine serum CK tests in various neuromuscular 
disorders [111, 155]. Blood circulating in the body collects proteins that are secreted or 
released from tissue, however, concentrations of tissue leakage proteins compared to 
classical serum proteins are lower by several orders of magnitude (reviewed in [115]). This 
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might be also the case for the muscle-specific HSPβ2 that could be found as a disease 
marker in serum due to leakage from damaged muscle tissue in DMD/BMD patients. Even 
though HSPβ2 is present at relatively high concentrations around 0.3µg/mg total protein in 
rat skeletal muscle [123] the concentration in serum due to leakage from damage tissue is 
unclear. Moreover, HSPβ2 is a cytosolic protein but is redistributed to the unsoluble protein 
fraction upon cellular stress [121], and poor solubility for purified recombinant HSPβ2 from E. 
coli has been reported [124]. We are currently aiming at the quantification of HSPβ2 in tissue 
lysates from primary human myotubes from DMD patients and controls. Unique peptides of 
HSPβ2 were detected previously in a shotgun LC-MS/MS experiment in primary human 
myotubes from DMD patients (data not shown) and preliminary experiments are carried out 
for the establishment of a selective SRM assay.  
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